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Summary
In its 2017 ‘Industrial Strategy’, the Government committed to raising total investment 
in research and development to 2.4% of GDP by 2027, and to reach 3% of GDP in the 
longer term. This compared to an investment of 1.69% in 2017, beneath the OECD 
average. We welcome the Government’s target, which—if achieved—would represent 
a significant increase in the research intensity of the UK economy. Although private 
sector investment will be critical to achieving this target, it is apparent that public 
investment will also be required and will gain greater traction if it is undertaken earlier. 
The Government should consider whether a separate Government R&D spending target, 
either as a proportion of GDP or in real terms, would benefit the current national target.
Both UKRI and BEIS have committed to producing roadmaps to show the path to 2.4%. 
We recommend that these are published as soon as possible and no later than the end 
of 2019. Plans contained in the roadmaps should show an integrated approach between 
UKRI and BEIS that suitably reflects the strengths and prospects of the UK economy. 
These plans should be developed beyond 2027 to ensure travel towards the longer-
term 3% target. In order to aid public understanding the roadmaps should update 
the Dowling Review schematic, including details of the main R&D funding streams 
available through the Industrial Strategy and UKRI.
The creation of UKRI created a significant opportunity for improving the strategy 
and co-ordination of research funding. We recognise the complexity of addressing the 
balance of funding of the dual support system, and that UKRI strategy is to approach 
the task cautiously and without any sudden shifts in funding. UKRI should also assess 
and report on other dimensions of balance such as the regional concentration of 
funding, the balance between research and innovation, and the balance between capital 
and current spending in a similar manner to its analysis of the dual support system. 
We believe more immediate changes to funding are appropriate to influence balance in 
these areas. There are many possible ‘balances’ or policy mixes, and this political choice 
should be transparently set out. UKRI should continually monitor the appropriateness 
of balances struck in the operation of the dual support system and publish the advice 
given to the Government, alongside analysis and commentary, at regular intervals.
We support UKRI’s commitment to evaluation, however the current focus appears 
too strongly to follow traditional metrics, measuring outputs such as publications 
and patents that should only be one element of evaluation. Research on research is 
an increasingly important field, and we recommend that UKRI consider a dedicated 
approach to supporting it, including how this research is incorporated into UKRI 
strategy and its assessment of the balance of R&D funding. Relatedly, UKRI should 
attempt to analyse the benefit gained by its creation through its enhanced ability to 
capture data across research councils and through cross-cutting funds. We recommend 
that UKRI also develops a ‘big data’ focus for evaluation. It should publish a plan for 
creating and investing in new data sources and analysis techniques beyond traditional 
measures of patents and publications.
The flat profile of quality-related (QR) funding in recent years suggests that it has not 
been prioritised in funding decisions, although the announcement of a £45 million 
increase in QR funding by Research England in July 2019 indicates that there may 
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be a change in this focus. We recommend that focus on QR funding is maintained 
in future considerations, and that QR should continue to be prioritised to address 
previous real-terms reductions in funding. We recognise, however, that the seven-year 
Research Excellence Framework (REF) cycle creates barriers for smaller but potentially 
fast-growing institutions or areas of excellence who receive lower QR allocations. We 
recommend that in UKRI’s ongoing evaluation work it reviews whether additional 
support for these institutions should be provided, possibly through specific gearing 
of investment across the REF period, through additional review periods for smaller 
bodies, or through separate QR stream for smaller and specialist institutions.
Place is a key focus within both the Industrial Strategy and the UKRI strategic prospectus 
and development plan. The Government should aim to build further research excellence 
outside of its existing predominance in the South East of England. We strongly agree 
that additional regional funding should not be to the detriment of this ‘golden triangle’. 
However, in order to contribute to the 2.4% R&D target, regional strengths will need to 
be harnessed and cultivated. For UKRI, the main lever with which to stimulate regional 
excellence is through the Strength in Places Fund (SIPF). The SIPF is still in its infancy, 
but its rationale and its goals remain somewhat opaque and it is too modest to drive any 
significant rebalancing of investment. We recommend that UKRI and BEIS substantially 
increase the size of the SIPF given it appears to be the primary lever through which it is 
attempting to influence the regional concentration of funding and create new centres of 
excellence beyond the golden triangle.
The balance across research disciplines should be easier to monitor and adjust under 
UKRI. Historic patterns clearly should not be maintained for their own sake. We are 
concerned that the Strategic Priorities Fund (SPF) may not have been established in 
a way that effectively addresses this. We recommend that UKRI review the SPF and 
ensure that individual research councils are not exerting excessive influence on what 
is intended to be a cross-council, multi-disciplinary focus. Future consideration of the 
balance between disciplines must include robust evaluation of research areas within 
each discipline. We find the case regarding entrenched concentration of research 
analysed in The Biomedical Bubble compelling. UKRI analysis should widen this 
approach and conduct relevant cost-benefit analysis of larger research areas within 
different disciplines to establish whether R&D spending remains productive.
We welcome the opportunity to redress reductions in capital investment for research. In 
order for UKRI to take ownership of the ‘batteries not included’ issue, we recommend 
that decisions for investment include consideration of the co-ordination of capital and 
revenue funding and the long-term requirements of new and existing investments. 
Major capital investment project plans should explicitly state assumptions regarding 
future QR or research council funding that may be required to staff or run them.
The Government strategy for reaching 2.4% R&D investment should highlight the 
significant R&D investment that is undertaken by Government departments. The 
Government needs to make it as easy as possible for businesses to locate and access 
opportunities to benefit from this investment, and should create a central linking point 
or web portal to facilitate this. The creation of UKRI represents an opportunity for it 
to operate as the ultimate steward of this system. The Government’s roadmap should 
5 Balance and effectiveness of research and innovation spending 
include detail on UKRI’s role in coordinating this investment. UKRI should analyse 
the potential impact of cross-Government funding on dimensions of balance such as 
regional concentration of spending.
We agree with the Connell Review that the Small Business Research Initiative (SBRI) 
has a “unique and valuable role to play in the innovation and procurement landscape”, 
supporting UK businesses in developing innovative new products while enabling public 
sector bodies to source innovative solutions to the challenges they face. However, the 
Government’s response to the Connell Review so far is limited. We recommend that the 
Government fully adopts the recommendations of the Connell Review, and establishes 
a central SBRI fund with a National Board to oversee its delivery as part of the 2020 
Spending Review.
Alongside increasing the size and reach of SBRI, the Government should produce a 
procurement strategy and communications plan that specifically identifies innovation 
opportunities and promotes innovation-friendly practices. It should address barriers 
currently perceived by the business community, such as treatment of risk and intellectual 
property. The benefits of a central portal that collates procurement opportunities from 
across Government should be pursued.
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1 Introduction
Background
1. In November 2017 the Government published its Industrial Strategy, Building a 
Britain fit for the future.1 The strategy identified five foundations of productivity for the 
UK, namely ideas, people, infrastructure, business environment and places. The first 
policy commitment made in the strategy, under the heading of “ideas”, was to raise total 
research and development investment to 2.4% of GDP by 2027, and to reach 3% of GDP in 
the longer term, “placing us in the top quartile of OECD countries”.2
2. At the same time, in response to Sir Paul Nurse’s Review of research councils in 
2015,3 the Higher Education and Research Act 2017 formally established UK Research 
and Innovation (UKRI) in April 2018. UKRI brought together seven research councils,4 
Innovate UK, and the research elements of the Higher Education Funding Council for 
England—now called ‘Research England’.
3. UKRI published its initial Strategic Prospectus in May 2018, representing the 
“beginning of the process to develop a detailed Research and Innovation Strategy”.5 
Regarding the 2.4% target for R&D spending, UKRI stated that it “will work with 
Government to develop a plan for meeting this target, maximising the impact of public 
investment in research and innovation, and supporting businesses and other partners to 
invest more”.6
4. The Higher Education and Research Act 2017 stated that the role of UKRI included 
advising Ministers regarding the balance between the dual support funding streams.7 
UKRI envisaged ongoing work to analyse and understand what constituted a reasonable 
balance.8
1 BEIS, Industrial Strategy, November 2017
2 BEIS, Industrial Strategy, November 2017, p 66
3 BEIS, Ensuring a successful research endeavour: review of the UK research councils by Paul Nurse, November 
2015; the review contained many recommendations that would be incorporated in to both the Industrial 
Strategy and UKRI, including the creation of a single organisation (UKRI) to improve communication and 
engagement between the research community and policy makers and establish common ways of working, a 
Ministerial committee for strategic discussions, a common research fund and increased ability for Government 
to invest in particular sectors, disciplines or regions. The report also recommended that dual support system of 
funding be preserved and that a principle of “investing in excellence, wherever it is found” be maintained.
4 Arts and Humanities Research Council; Biotechnology and Biological Sciences Research Council; Engineering and 
Physical Sciences Research Council; Economic and Social Research Council; Medical Research Council; Natural 
Environment Research Council; and Science and Technology Facilities Council.
5 UKRI, Strategic Prospectus, May 2018, p6
6 UKRI, Strategic Prospectus, May 2018, p11
7 Under the ‘dual support’ system, Research England will provide annual funding for English institutions in 
the form of a ‘block grant’, and UK Research Councils provide funding for specific research projects and 
programmes. See Chapter 5 for further details.
8 UKRI, Strategic Prospectus, May 2018, p23
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Our inquiry
5. In July 2018 we launched an inquiry to look at the balance and effectiveness of research 
and innovation spending, to identify and understand the levers and choices available to 
aid the Government and UKRI in reaching the Government’s 2.4% target. In the call for 
evidence we highlighted the need to understand the rationale required for deciding the 
balance of public R&D funding against many different criteria, including:
• individual research disciplines, research councils and cross-disciplinary 
schemes;
• the two research funding streams of the ‘dual support’ system;
• ‘pure’ and ‘applied’ research;
• research and innovation;
• block funding, responsive mode funding and directed funding;9
• the ‘golden triangle’ of London, Oxford and Cambridge, and the rest of the UK; 
and
• global challenges and other strategic/national priorities
6. We also wished to assess the effectiveness of this public spending, in light of new 
funding streams such as the Industrial Strategy Challenge Fund. With the next Spending 
Review then expected in 2019 we asked for information regarding the phasing and 
plans required to meet the Government’s targets, and assumptions about the private 
sector investment that would be necessary alongside Government spending. As such we 
were also interested in the effectiveness of different levers for encouraging innovation, 
including R&D tax credits, the Small Business Research Initiative, and other loans and 
grants available for private enterprise.
7. Given the scope of inquiry and the number of actors involved across Government, 
universities and business—and the linkages between them—we received a high number 
of written evidence submissions (around 100). We also took oral evidence from 29 
witnesses including the then Minister for Universities, Science, Research and Innovation 
and the Chief Executive of UKRI, as well as academics, international experts on research 
and development, and representatives of universities, business, and charities. To assist 
us in our work, we also appointed Dr Kieron Flanagan, Senior Lecturer in Science and 
Technology Policy at Manchester Institute of Innovation Research, as a Specialist Adviser 
for our inquiry.10 We are grateful to everyone who contributed to our inquiry.
9 The terms of reference considered directed funding for the Industrial Strategy
10 Dr Flanagan declared his interests on 13 November 2018: Senior Lecturer in Science and Technology Policy, 
Manchester Institute of Innovation Research, University of Manchester: an employee of the University of 
Manchester and an elected member of that university’s Senate
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8. In this Report we set out recommendations for the Government and UKRI that we 
believe will be important in ensuring the 2.4% and 3% targets for R&D as a proportion of 
GDP are met. Specifically:
• In Chapter 2 we consider the level of ambition of the 2.4% target and how this 
compares in an international context, which influences how such targets should 
be viewed and interpreted;
• In Chapter 3 we detail the role and structure of UKRI in the complex wider 
R&D landscape. This complexity highlights the challenges facing UKRI;
• In Chapter 4 we explore the balance issues across the different dimensions and 
disciplines that UKRI will need to consider when making its funding allocations; 
and
• Finally, in Chapter 5, we look beyond UKRI to the other channels of influence 
that the Government has in incentivising increased R&D, through Government 
spending, taxation and regulation.
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2 Level of ambition of the 2.4% target
9. This Chapter considers the importance of research and innovation spending, and 
details the current level and composition of spending in the UK. In this context, and 
compared to spending in other countries, we consider whether the current target of 2.4% 
of GDP should be viewed as an ambitious one. We also identify other factors that will be 
of importance in reaching this goal.
Importance of research and innovation spending
10. The Department for Business, Energy and Industrial Strategy (BEIS) highlighted in 
its submission that “research and innovation are vital to our country’s prosperity, security 
and wellbeing, and an integral part of delivering the UK’s Industrial Strategy”.11 UK 
Research and Innovation (UKRI) summarised the importance of investment in R&D and 
the positive social returns it had (i.e. additional value created for others in society, beyond 
those undertaking the investment):
There is significant national and international evidence that shows public 
investment in R&D achieves high social rates of return, of around 20% p.a. 
It attracts substantial private investment in R&D from within the UK and 
overseas, with every £1 of public spend leveraging about £1.40 of private 
spend. Private R&D investment also leads to significant benefits, with 
direct returns to the firm of about 20% p.a. and social returns two or three 
times this.
The evidence suggests that on average £1 of public R&D investment 
generates around £7 of net benefit to the UK.1213
11. The R&D target therefore represents a path of increased spending that will benefit 
the whole of the UK economy through these ‘spill over’ effects. The Industrial Strategy 
suggested that doing so will “transform our economy”:
with our businesses creating the next generation of technologies to 
revolutionise productivity in all sectors from construction and agriculture 
to manufacturing and the creative industries. This will raise the standard of 
living and establish UK leadership in global markets.14
Current R&D spending
12. The Government has set targets for R&D spending to constitute 2.4% of GDP by 
2027, and to reach 3% of GDP in the longer term. The latest ONS data15 shows that in 2017 
total R&D expenditure in the UK was £34.8 billion, or 1.69% of GDP, but the breakdown 
of this spending is complex16 and dependent on whether split by funding source or by the 
sector in which R&D is performed. The Frascati Manual (the internationally recognised 
11 Department for Business, Energy and Industrial Strategy (BER 0064)
12 UK Research and Innovation (BER0063) para 7
13 Similar effects were highlighted in many submissions, including The British Academy (BER0042) para 27 and 
Academy of Medical Sciences (BER0069) p3
14 Industrial Strategy p66
15 ONS, Gross domestic expenditure on research and development, UK: 2017, March 2019
16 The British Academy (BER0042) para 27
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methodology for collecting and using R&D statistics), categorises investment from four 
sectors: business enterprise; Government (including research councils); higher education; 
and private non-profit organisations (such as charities).17 Investment by business and 
non-profit organisations may originate domestically or from overseas.
13. In terms of funding, the UK business sector funded £18.7 billion of total UK-
performed R&D activity, representing around 54%. The Government sector was the 
second-largest source of funding at £6.8 billion or 20%. However, whilst this includes 
funding by the seven research councils of £3.7 billion, it excludes funding by the higher 
education funding councils (HEFCs) for England, Scotland, Wales, and the Department 
for Employment and Learning in Northern Ireland. An alternative split shows funding by 
Government departments of £3.7 billion (11%) and dual support funding through HEFC 
and Research Councils of £5.3 billion (15%). Around £5 billion (14%) of UK R&D funding 
is from overseas investment.
14. The figure below, published by the Office for National Statistics (ONS), represents 
these flows of funding through the R&D ecosystem. The values in the boxes are the 
amounts of funding that each sector provided to the recipient performing sector.
Figure 1: Flows of Research and Development Funding, Office for National Statistics (2019)
17 OECD, Frascati Manual 2015, October 2015
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15. In terms of R&D activity, business R&D represents the largest share at £23.7 billion 
in 2017, or 68% of total UK R&D expenditure. The product groups with the largest 
R&D activity were pharmaceuticals (£4.3 billion), vehicles and parts (£3.6 billion), and 
computer programming and information services (£1.9 billion). The higher education 
sector accounts for R&D activity of £8.2 billion, or around 23% of total UK expenditure, 
mainly provided through the dual support system by research council and HEFC funding 
as shown above. The statistics show R&D activity in the UK Government department 
research institutes and laboratories of £2.2 billion, or 6% of total R&D activity. Private non-
profit organisations undertook a further £0.8 billion of activity, or 2% of total spending.
16. The ONS data suggests that R&D spending of 1.69% in 2017 was an increase from 
1.67% the previous year. However, OECD data suggested there was a decrease from 1.68% 
to 1.66%, although this may be revised in light of the more recent ONS figures.18
17. In terms of international comparison, using UNESCO data these levels are similar 
to Canada and Norway, but lower than France (2.3%), Germany (2.9%) and behind table 
leaders such as South Korea and Israel (both 4.2%).19
18. The target of 2.4% of GDP represents the current OECD average spend on R&D; a 
briefing by the Royal Society illustrated the gap between current level of UK investment, 
the OECD average, and the eventual target in the figure below.20
Figure 2: UK R&D funding, Royal Society (2019)
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2.4% as a ‘stretch’ target
19. The Campaign for Science and Engineering (CaSE) submitted to us modelling of the 
additional private and public investment required to meet the 2.4% target. The baseline 
assumption used by CaSE was that without increased Government investment public 
expenditure remained flat in cash terms and private expenditure increased in line with 
GDP; and that additional public investment would leverage further private spending at a 
ratio of 1.36. Their results showed that “public investment must reach £20 billion in 2027, 
[an] additional £9 billion per year” if the UK is to reach its 2.4% target.21 This additional 
spending is shown in the figure 3 below.
Figure 3: Additional Funding required to meet R&D targets, CaSE (2018)
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20. Several conclusions flow from this result, notably that the public investment portion 
of research and development spending must be frontloaded to achieve sufficient leverage 
of private investment to achieve the target of 2.4% by 2027. CaSE explained that UKRI 
and BEIS could not deliver public investment by themselves so cross-Governmental R&D 
spend “will be crucial to meet the target”.22 However, whilst these are the implications of 
the modelling, they do not consider the capacity of the research system to absorb these 
increases and spend money effectively.
21. Rebecca Endean representing UKRI commented that, with the latest ONS data 
showing that “£34 billion is spent on R&D in the UK. To get to 2.4%, that number will 
have to double in nominal terms”.23 Professor Sir Mark Walport, Chief Executive, UKRI, 
also added that a whole-economy approach was needed: “you also need to think about the 
denominator. What the overall economy does is very critical as well.”24 The then Minister 
21 Campaign for Science and Engineering (BER0065)
22 Campaign for Science and Engineering (BER0065)
23 Q398
24 Q399
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of State for Universities, Science, Research and Innovation, Chris Skidmore MP, noted that 
this did make the target a “slightly perverse one” as “we want to have a strong economy 
and recognise that investment in R&D can deliver that strong economy.”25
22. There was an element of disagreement in the evidence received regarding the ambition 
of the target. Kirsten Bound of Nesta summarised this conflict when she explained:
from one perspective, it is monumentally ambitious. It requires a sustained 
year-on-year increase that we have not seen in a generation. From another 
perspective, it will take us to an OECD average intensity spend. No country 
aspires to be average.26
23. Sir Paul Nurse agreed that the target was “a step in the right direction, but you cannot 
say that it is that ambitious”,27 whilst Mr Polcuch of UNESCO also raised the point that 
were the UK to move towards 2.4% it would necessarily by 2027 be under the OECD 
average.28
24. The interpretation of the target as ambitious was partly due to the recognised difficulty 
in pushing through substantial increases in R&D investment. Kirsten Bound suggested 
that “several countries have achieved this kind of increase in the past”, but that “input 
intensity targets are hard to meet”.29 Professor Edler of the German Fraunhofer Institute 
for Systems and Innovation Research noted that “there are countries in Europe that have 
done it [ … ] It can be done [… but] there is a decreasing return on R&D investment at 
some point”.30 This is partly reflected in previous UK R&D targets which were unmet, 
notably a 2004 commitment to reach 2.5% of GDP by 2014.31 A quarter of this increase 
was sought from public funding and three quarters from private; while there was a modest 
increase in private R&D investment over this period, publicly-funded R&D remained flat 
as a share of GDP.32
25. However, international comparisons themselves may be of limited use. Dr van 
Broek of the Raathenau Instituut in Holland suggested “you should think more about 
understanding what you want to achieve than just about trying to get to 2.4%”.33 Similarly, 
there was agreement between the international experts giving evidence that it was not 
desirable to simply copy traits of other systems; they argued that the UK needed to look 
at its own economic structure and identify where strengths were now and where they 
might be in the future, and this should dictate the “effectiveness” of any investment.34 
This suggested that the goals of science and innovation policy and the Industrial Strategy 
must be kept at the forefront of investment decisions, ensuring a focus on quality as well 
as quantity of research funding.
26. With these points in mind, it was clear that reaching suitable settlements in the next 
Spending Review and any further spending settlements up to 2027 would be crucial. 
25 Q453
26 Q2
27 Q3
28 Q54
29 Q3
30 Q51
31 HM Treasury, Science and innovation investment framework 2004–2014, July 2004
32 UK Research and Innovation (BER0063) para 40
33 Q100
34 Q70
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This was echoed by UKRI and BEIS. Professor Sir Mark Walport said that “in order to 
maintain the trajectory, we will be making a very strong case as part of the spending 
review, through BEIS, that we are heading in the right direction, but a lot more needs to be 
done.”35 The then Minister agreed that “the spending review is completely critical”36 and 
that “if we do not get it right this year we will struggle to get to 2.4% by 2027”,37 adding:
I am also chastised by the fact that, when you look at figures published on 
14 March [2019] by the ONS, total R&D expenditure in 2017 represented 
1.69% of GDP, up from 1.67% in 2016. We put an additional £7 billion into 
R&D between 2016 and 2021. To hit 2.4% is going to be a challenge and I 
want to make sure I can commit to meeting it effectively by a 0.1% uplift 
every year.38
27. Additional frontloaded funding will be key for reaching the 2.4% target, but 
it clearly is not sufficient. It is also important to ensure that the capacity of the UK 
economy and research system enables R&D expenditure to be used efficiently and 
effectively. Creating sufficient leverage of private sector investment will be crucial. The 
Government should consider whether a separate Government R&D spending target, 
either as a proportion of GDP or in real terms, would benefit the current national target.
28. UKRI and BEIS sought to assure us that work was underway to better understand the 
research and innovation landscape (see Chapter 3 for an explanation of the complexity of 
this landscape). UKRI’s engagement was demonstrated by its work on the ‘research and 
innovation infrastructure roadmap’—an assessment of existing UK infrastructure, and 
analysis of future economic and social needs, and the resulting investment priorities.39 The 
latest update was published in March 2019.40 UKRI have suggested that they will publish 
their roadmap in “summer or autumn”.41 BEIS is also developing a roadmap and have 
committed to publishing theirs “shortly after the spending review”.42 These are envisaged 
to sit “side by side”.43 BEIS has also continued to undertake related assessments through 
the ‘science and innovation audits’ (SIA), aimed at helping local and regional areas to map 
their research strengths and identify areas of potential global competitive advantage.44 
Whilst the SIA appear beneficial for understanding the baseline environment in the UK, 
they do not themselves directly address the challenge of reaching the 2.4% target.
29. Plans such as the roadmaps are inevitably complex undertakings given the range 
of actors involved. UKRI assured us that they were “working with partners across 
Government” in developing theirs,45 and similarly that they were engaging with BEIS 
in gathering evidence and engaging with stakeholders for the Government’s version.46 
Rebecca Endean representing UKRI summarised the need for an expansive view of what 
would contribute to the target:
35 Q400
36 Q453
37 Q452
38 Q453
39 UKRI Research and Innovation Infrastructure Roadmap
40 UKRI UKRI Infrastructure Roadmap Progress Report
41 Q389
42 Q461
43 Q460
44 BEIS Science and innovation audits
45 Q388
46 Q389
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We need to think about what our offering is around place, infrastructure 
and industry support. A range of other Government policies will need to 
support and encourage the R&D, through tax incentives, regulation… 
What we are trying to do, working with BEIS, is to think about that road 
map in a very holistic sense. UKRI is very important, of course, but it 
is not just about UKRI. It is about how UKRI fits into that wider cross-
Government initiative, where we look at all the policy instruments around 
place, infrastructure, people and supporting business.47
30. The then Minister also recognised the difficulty inherent in planning towards a 
target in 2027 when the Spending Review was for a significantly shorter period, with 
the “interesting challenge” that the review period will be for “three years rather than, 
traditionally, four years.”48 He said that the publication of the roadmap would follow the 
Spending Review when “we know exactly how much money we have in the bag from the 
Treasury”.49
31. The Chancellor has subsequently confirmed that the next multi-year Spending 
Review will not be carried out until 2020, and instead on 4 September delivered a one-year 
Spending Round detailing departmental funding allocations for the 2020–21 financial 
year.50 The Spending Round re-iterated the Government’s commitment to the 2.4% target:
The government is committed to increasing levels of research and 
development (R&D) to at least 2.4 per cent of GDP by 2027. In the autumn, 
the government will set out plans to significantly boost public R&D 
funding, provide greater long-term certainty to the scientific community, 
and accelerate its ambition to reach 2.4 per cent of GDP.51
However, it is also noted that whilst the majority of BEIS’s capital settlement funds R&D, 
an accounting change meant that BEIS’s capital budget had not been fully set for 2020–21.52 
The documentation currently shows the BEIS capital budget decreasing from £11.5 billion 
in 2019–20 to £6.4 billion in 2020–21, a reduction of £5.1 billion. Across Government 
there is an additional £6.5 billion unallocated capital budget for 2020–21 for which the 
departmental allocations will be “confirmed before 2020–21”.53
32. Little mention was made in evidence of the “longer-term ambition of 3%.”54 Achieving 
the initial target is a clear precursor to this aim, but it was left unclear whether success in 
meeting the initial target would put in place a trajectory that could be followed beyond 
that.
33. We welcome the Government’s target for R&D spending which, if achieved, would 
represent a significant increase in the research intensity of the UK economy. However, 
the difficulty in achieving the target should not be underestimated, and will require 
successful coordination of public spending and further increases in private investment.
47 Q398
48 Q462
49 Q458 [Chris Skidmore]
50 HM Treasury, Spending Round 2019, September 2019
51 HM Treasury, Spending Round 2019, September 2019 para 2.35
52 HM Treasury, Spending Round 2019, September 2019 p18
53 HM Treasury, Spending Round 2019, September 2019 p34
54 Q453
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34. We welcome the commitments by UKRI and BEIS to make a strong case at the 
Spending Review, which we had expected to be this autumn, for the additional funding 
required to reach the 2.4% target by 2027. Given the stretch of the target, it is apparent 
that additional public spending is likely to gain greater traction if it is undertaken 
earlier, thus increasing the potential for leveraging private sector spending.
35. Both UKRI and BEIS have committed to publishing roadmaps to show the path 
to 2.4%. It is our understanding that given the nature of both public and private 
investment required to reach the target, these roadmaps will address the landscape 
influencing R&D spending, including the wider Government policies and pillars of the 
Industrial Strategy (ideas, people, infrastructure, business environment, and places).
36. It is not clear whether the Government’s recent commitment to “set out plans to 
significantly boost public R&D funding”, which it had promised this autumn, relate 
specifically to the roadmaps, high-level long-term funding plans, or simply greater 
clarification of the BEIS capital budget for next year, which was not fully set in the 
recent Spending Round. Assuming that a multi-year funding commitment is made, 
a “significant boost” should suitably reflect the frontloaded investment that we have 
established is required. We are pleased that such decisions will not be delayed until the 
2020 Spending Review and urge UKRI and BEIS to make the ‘strong case’ we expect of 
them.
37. We hope that the promise of providing “greater long-term certainty to the scientific 
community” indicates both a long-term funding commitment and the detailed plans we 
expect to be contained in the roadmaps. If not, we strongly recommend that both UKRI 
and BEIS publish their promised comprehensive roadmaps to illustrate the intended 
path to the 2.4% target as soon as possible, and no later than the end of 2019 following 
confirmation of Government funding plans. These should demonstrate an integrated 
approach between UKRI and BEIS that suitably reflects the strengths and prospects of 
the UK economy. These plans should also be developed beyond 2027 to ensure that travel 
towards the longer-term 3% target, indicating how momentum will be maintained and 
when more detailed plans for this target will be produced.
17 Balance and effectiveness of research and innovation spending 
3 UKRI and the R&D landscape
38. The creation of UKRI represents a significant change to the UK research and innovation 
landscape, one which has already been adapting to policies and strategy contained in the 
Government’s Industrial Strategy. In this Chapter we examine the complexity of the R&D 
landscape, and detail the additional funding streams created and administered through 
the Industrial Strategy and UKRI. We then outline the significant challenges for strategy 
and evaluation of policy that UKRI will face.
Complexity of the R&D landscape
39. In July 2015 the Government published the independent Dowling Review of 
Business-University Research Collaborations, to develop advice on how the Government 
can support relationships between UK businesses and UK university researchers.55 The 
review identified business research and development as the foundation of productivity 
and growth and made recommendations to better support relationships between business 
and university researchers. As part of its research the review attempted to map the UK 
research and innovation landscape, identifying the channels through which business and 
university interacted, as shown in figure 4 overleaf.
55 Department for Business, Energy and Industrial Strategy, The Dowling Review of Business-University Research 
Collaborations, July 2015
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37 Figure 10 is an attempt to capture the major organisations and funding sources, relevant to business-university collaboration, in the UK’s research and 
innovation landscape. Due to the complexity of the landscape there will inevitably be information missing. 
State of play: collaborative research in the UK 
19 Balance and effectiveness of research and innovation spending 
40. The review noted that “due to the complexity of the landscape there will inevitably 
be some information missing”. Consequently the review summarised the challenges of a 
complex innovation ecosystem:
Business-university collaboration is an important component of the 
innovation ecosystem. Innovation is a complex, non-linear process, so the 
complexity of the UK’s innovation ecosystem is not surprising and may 
be to a degree inevitable. However, the complexity of the policy support 
mechanisms for research and innovation poses a barrier to business 
engagement in collaborative activities, especially for small businesses. It 
also makes it difficult for government to take a systems view of its support 
mechanisms for research and innovation.56
41. As established in the previous Chapter, achieving a 2.4% target for R&D as a 
proportion of GDP will require a significant increase in public and private investment. 
This will require the Government to create an effective policy mix across the entire R&D 
landscape in order to effectively leverage public spending. Changes to the research and 
innovation ecosystem since the Dowling Review, in particular the Industrial Strategy and 
creation of UKRI, represent “considerable changes” in the UK R&D landscape.57 However, 
these changes created new policies and funding streams which could potentially add 
complexity. The sections below examine some of these policy developments and identify 
the challenges they have created.
42. The complexity of the R&D ecosystem has been well documented and means that 
understanding the interaction of organisation, funding and policies is difficult. Some 
complexity may be inevitable given the diversity of policy goals and actors. UKRI and 
BEIS should ensure that their roadmaps on how the UK will reach the 2.4% target detail 
key areas of potential conflict or policy overlap resulting from their choice of policy mix in 
this complex environment. Unnecessary complexities should be identified and removed 
as part of the mapping process. In order to aid public understanding they should update 
the Dowling Review schematic, including details of the main R&D funding streams 
available through the Industrial Strategy and UKRI.
The Government’s Industrial Strategy
43. The Government’s Industrial Strategy stated that its central objective was to improve 
living standards and economic growth across the country. The 2.4% R&D target was a 
fundamental pillar of its approach. The strategy incorporated the National Productivity 
Investment Fund (NPIF), a £37 billion fund for capital investment between 2017–18 
and 2023–24. The Fund covers housing, transport and digital infrastructure as well as 
R&D funding, for which £7 billion was allocated from 2017–18 to 2021–22.58 Relatedly 
the Government has created ‘Sector Deals’ outlining partnerships between Government 
and industry in areas such as construction and rail, aiming to ‘transform’ the sector’s 
productivity through innovative new technologies.59
56 Department for Business, Energy and Industrial Strategy, The Dowling Review of Business-University Research 
Collaborations, July 2015, p2
57 AIRTO Ltd (BER0013) p1
58 HM Treasury, Autumn Budget 2018, Nov 2018, p54
59 BEIS, Introduction to Sector Deals
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44. The Industrial Strategy set out a series of Grand Challenges to “put the UK at the 
forefront of the industries of the future, ensuring that the UK takes advantage of major 
global changes, improving people’s lives and the country’s productivity”.60 The first four 
‘grand challenges’ were: artificial intelligence and data; ageing society; clean growth; and 
the future of mobility.
45. Within each of these challenges were more specific missions, focusing on a specific 
problem in order to bring together Government, businesses and other organisations. For 
example the AI and data mission was to “use data, artificial intelligence and innovation 
to transform the prevention, early diagnosis and treatment of chronic diseases by 2030.”61
46. These challenges have informed one of the major R&D policies introduced by the 
Government, namely the UKRI-operated Industrial Strategy Challenge Fund (ICSF). We 
discuss this further in the section below, alongside other funds operated by UKRI.
The creation of UKRI
47. UK Research and Innovation (UKRI) is a non-departmental public body that was 
formally established in April 2018 through the Higher Education and Research Act 2017,62 
following Sir Paul Nurse’s Review of UK Research Councils in 2015.63 The creation of 
UKRI united the most significant elements of public sector R&D funding, bringing 
together the seven sectoral research councils64 with Innovate UK and Research England 
(whilst the devolved administration equivalents of Research England remain in place). 
The current funding allocation for these councils is shown below.65
Figure 5: UKRI funding allocation 2018–19, UKRI Strategic Prospectus (2018)
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60 BEIS, The Grand Challenges
61 BEIS, The Grand Challenges missions
62 Higher Education and Research Act 2017
63 Department for Business, Innovation and Skills, Ensuring a successful research endeavour: a review of the UK 
research councils by Sir Paul Nurse, Nov 2015
64 Arts and Humanities Research Council; Biotechnology and Biological Sciences Research Council; Engineering and 
Physical Sciences Research Council; Economic and Social Research Council; Medical Research Council; Natural 
Environment Research Council; and Science and Technology Facilities Council.
65 UKRI Strategic Prospectus, May 2018
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48. In its case for the creation of UKRI the Government highlighted a range of benefits 
stemming from integrating these research and innovation functions within a single body.66 
These included:
• a greater focus and capacity to deliver on cross-cutting issues that are outside the 
core remits of the current funding bodies, such as multi- and inter-disciplinary 
research;
• a strengthened, unified voice for the UK’s research and innovation funding 
system, facilitating the dialogue with Government and partners on the global 
stage;
• improved collaboration between the research base and the commercialisation of 
discoveries in the business community;
• better mechanisms for the sharing of expertise and best practice—for example, 
around management of major projects and large capital investment;
• more time for research and innovation leaders to focus on strategic leadership 
through the centralisation of back and middle office functions and the reduction 
of administrative responsibilities; and
• improved quality of evidence on the UK’s research and innovation landscape 
through the pooling of multiple datasets and information sources, underpinning 
effective funding decisions.
49. Within UKRI the research councils are responsible for funding and co-ordinating 
academic research within their field, as well as funding postgraduate study. Council 
funding is project-orientated, representing one pillar of the ‘dual support’ system.67 Similar 
to the Grand Challenges of the Industrial Strategy, individual research councils have their 
own themes, with, for example, the Engineering and Physical Sciences Research Council 
(EPSRC) listing 12 themes including digital economy, energy and engineering.68
50. In addition to these seven research councils UKRI incorporates the new council 
‘Research England’. This takes forward the England-only research responsibilities of the 
Higher Education Funding Council for England (HEFCE), responsible for the block grant 
funding element of the dual support system.69 Although UKRI incorporates Research 
England, there are separate HEFCs for devolved administrations—the Scottish Funding 
Council, the Higher Education Funding Council for Wales, and the Department for the 
Economy in Northern Ireland, which maintain powers to work jointly with Research 
England and UKRI.
51. The final organisation incorporated into UKRI was Innovate UK. It works with 
people, companies and partner organisations to drive science and technology innovations, 
66 BEIS Case for the creation of UK Research and Innovation, June 2016
67 The dual support represents the two main funding lines of UKRI, and can be thought of project-orientated 
elements and block grants. For more discussion see Chapter 5.
68 Engineering and Physical Science Research Council, Themes
69 The dual support system refers to the split in funding for institutions between the research councils project 
funding and the annual ‘block grant’ funding provided by Research England. This is discussed in detail in 
Chapter 4.
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for example through the Knowledge Transfer Network (KTN).70 Innovate UK is also 
responsible for the Catapult network of R&D centres which connect businesses with 
research and academic communities.71 It also delivers the Small Business Research 
Initiative, a programme aimed at delivering improved public services through harnessing 
innovative solutions from business to challenges faced by Government.72 The Innovate 
UK model is significantly younger than the research council model and the scale and 
scope of activity has grown rapidly from a small base.
52. The aim of increasing capacity to deliver on cross-cutting issues is demonstrated 
through UKRI’s administration of a number of cross-cutting funds, created in line with 
the priorities of the Industrial Strategy and funded through the National Productivity 
Investment Fund. The list below details those outlined in BEIS’s allocation documentation:
• Industrial Strategy Challenge Fund (£491 million in 2019–20): fifteen challenges 
“informed by industry”, these focused on “specific areas where either the UK 
already has world-leading research and businesses ready to innovate, or where 
the global market is large or fast-growing and sustainable”. Whilst these 
challenges are informed by the Industrial Strategy Grand Challenges (ISGCs), 
Nesta has called for a “stronger link” with the ISGCs and a review of the fund to 
make sure it is challenge led.73
• Strength In Places Fund (£32 million in 2019–20): funding to support significant 
local economic growth, by supporting areas of R&D strengths that are driving 
clusters of businesses that have potential to innovate, so that those clusters 
become nationally and internationally competitive.74 It also aims to enhance 
local collaborations between universities.
• Future Leaders Fellowships (£900 million over the next 11 years75): aimed at 
helping the “next generation of researchers, tech entrepreneurs, business leaders 
and innovators” to get the support required to develop their careers by providing 
up to seven years of funding for around 550 early-career researchers from the 
UK and abroad in UK-based universities and businesses76 (subject to certain 
eligibility criteria77).
• Strategic Priorities Fund: building on Sir Paul Nurse’s recommendation of a 
common fund support for multidisciplinary and interdisciplinary programmes 
identified by researchers and businesses. The multidisciplinary programmes 
are coordinated through the combinations of relevant research councils in six 
‘priority areas’, including tackling antimicrobial resistance and global food 
security.78
70 KTN is a network partner of Innovate UK that provides advice on funding, industry expertise and connections to 
other sectors through a network of businesses, universities, funders and investors.
71 There are ten Catapult centres, with a total budget of around £100 million; Cell and Gene Therapy, Digital, 
Future Cities, High Value Manufacturing (a network of another seven centres), Offshore Renewable Energy, 
Satellite Applications, Transport Systems, Medicines Discovery, Compound Semiconductor Applications, and 
Energy Systems
72 Innovate UK Small Business Research Initiative
73 Nesta (BER0072) para 2.3
74 UKRI Strength in Places Fund
75 UKRI Background to the Scheme
76 UKRI Background to the Scheme
77 UKRI Future Leaders Fellowship: Person Specification
78 UKRI Themes and Programmes
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• Commercialisations: includes the £210 million Higher Education Innovation 
Fund administered by Research England to support interactions between 
English universities and “the wider world”,79 and the £100 million Connecting 
Capability Fund for collaboration between English universities in research 
commercialisation.80
• The UK-wide Fund for International Collaboration (£110 million): focusing on 
bilateral and multilateral partnerships with global R&D leaders.
53. The UKRI Strategic Prospectus (figure 6 below) illustrated how this funding was 
distributed:81
Figure 6: UKRI Funding through National Productivity Investment Fund, UKRI Strategic Prospectus 
(2018)
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54. In addition, UKRI also administers the UK-wide Global Challenges Research Fund 
(GCRF), aimed at supporting research that addresses challenges faced by developing 
countries across three challenge areas (equitable access to sustainable development; 
sustainable economies and societies; and human rights, good governance and social 
justice).82 This forms part of the UK’s Overseas Development Assistance (ODA) and aims 
to tackle the UN’s Sustainable Development Goals. UKRI also administers the Newton 
Fund,83 another part of UK ODA that supports economic development with partner 
countries. GCRF and Newton Funding thus count both towards the Government’s 2.4% 
R&D target and towards the Government’s 0.7% overseas aid target.
79 UKRI The Higher Education Innovation Fund (HEIF)
80 UKRI The Connecting Capability Fund (CCF)
81 BEIS, The allocation of funding for research an innovation, July 2018 p12
82 UKRI Global Challenges Research Fund
83 UKRI Newton Fund
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Challenges for UKRI
55. The significant majority of evidence we received expressed support for the creation 
of UKRI, its aims, and for the opportunities it represented. This included universities, 
professional organisations, business and charities.84 But as with any newly established 
organisation there are also inherent risks.85 The main challenges identified in our inquiry 
predominantly related to strategy and evaluation.
Strategy
56. Sir Paul Nurse argued that the previous research council structure created a “lack 
of decision making”, and that the formation of UKRI meant there was an opportunity 
to take on strategy discussions that “are both exceptionally important and quite difficult 
to do well.”86 The innovation Foundation Nesta suggested that the creation of UKRI was 
a “huge opportunity to do things better, and not just to remake the existing system on a 
grander scale”.87 The Campaign for Science and Engineering suggested that such a strategy 
required a “clear vision of the purpose of increasing the R&D intensity of the UK”.88 We 
discuss later in this Report the balance between the different dimensions of research and 
innovation in the development of this strategy.
57. The UKRI strategy has continued to progress during the course of our inquiry. The 
Strategic Prospectus published in May 2018 set out the initial vision, mission and values 
that would inform this development of UKRI, and focused on “pushing the frontiers of 
human knowledge and understanding”, with the aim of “delivering economic impact” 
and “creating social and cultural impact by supporting our society to become enriched, 
healthier, more resilient and sustainable”.89 However, this only represented the “beginning 
of a process to develop a detailed Research and Innovation Strategy” in order to answer 
a “series of big questions”.90 The prospectus contained various commitments, such as to 
the Haldane principle,91 support for a balanced dual support funding system, building a 
culture of evaluation, and support for growth across the UK. It also set out several pieces 
of ongoing work that would help to refine the UKRI strategy:92
i) “We will develop a longer-term Research and Innovation Talent Strategy in 
2018” (p.15);
ii) “In its first year, UKRI will engage with its stakeholders to develop a strategy 
and action plan for equality, diversity and inclusion” (p.16);
84 Russell Group (BER0060); Academy of Medical Sciences (BER0069);The Confederation of British Industry (CBI) 
(BER0026)
85 Deloitte Managing the Execution Risks of Change Initiatives: Risks of organisational restructuring could be that 
a focus on establishing the organisation and processes may mean wider opportunities are missed, the creation 
of groupthink could harm the diversity of research funding, or potential ‘regulatory capture’ (such that Innovate 
UK is seen increasingly as the tech transfer arm of research councils, rather than equally reflecting private sector 
interests)
86 Q6
87 Nesta (BER0072) page 1
88 Campaign for Science and Engineering (BER0065) page 1
89 UKRI Strategic Prospectus p6
90 UKRI Strategic Prospectus p5
91 The Haldane principle states that whilst the government sets the overall strategic direction that research should 
take, decisions about which research projects to fund are taken by experts in the field through peer review.
92 UKRI Strategic Prospectus, as identified by WonkHE Seven things we have learned from the launch of UKRI’s 
strategy, May 2018
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iii) “We will scope a new UKRI Ethics Policy and Framework” (p.17);
iv) “We will review our open access [data] policies to assess their 
effectiveness and make recommendations in 2019” (p.19);
v) “We will develop effective data and metrics to understand the research 
and innovation landscape in different sectors, technology domains and 
places” (p.28); and
vi) “We will review our public engagement programmes and develop a new 
public engagement vision and strategy by March 2019” (p.39).
58. UKRI has subsequently published its 2019–20 Delivery Plans, highlighting the “areas 
of focus and key activities of UKRI’s nine constituent councils and its cross-cutting 
themes.”93 However, progress on many of the other commitments is less clear. We address 
the issue of evaluation in the next section.
59. Regarding public engagement, Sir Paul Nurse emphasised the importance of scientists 
earning their “licence to operate”, “by engaging the public and getting them on board”,94 a 
sentiment supported by Professor Sir Mark Walport, Chief Executive of UKRI.95 However, 
the evidence for UKRI’s work in fostering this licence to operate, as published on the 
UKRI website, appears largely based on investments made by research councils over the 
last decade,96 rather than through a new public engagement strategy as committed to in 
the prospectus. The review of open access to data appears to be ongoing, and due to launch 
in March 2020, although there will be no change to the Research Excellence Framework 
(REF) 2021 open access policy.97
60. The main area which appears to be lacking in the UKRI strategy is the review of 
balance that this Report addresses. The prospectus commits to continuing “to champion 
both responsive and strategic modes of funding to enable discovery-led research to flourish 
in the UK and drive impact from new knowledge and breakthroughs”, whilst the delivery 
plan states that UKRI is:
undertaking a programme of evidence gathering and analysis on the dual 
support system [ … ] to better understand the pressures facing the higher 
education sector, the impact of different funding scenarios, and to provide 
advice to ministers on the most appropriate balance of funding.98
61. Whilst there is additional detail regarding funding allocations for the ICSF, Strength 
in Places Fund and Strategic Priorities Fund, there is no detail regarding how these 
decisions were made, or their impact on balance of funding across the dimensions that we 
address in this Report.
62. The creation of UKRI created a significant opportunity for improving the strategy 
and coordination of research funding. However, there remain significant risks in 
93 https://www.ukri.org/about-us/delivery-plans/
94 Q10
95 Q401
96 UKRI Embedding public engagement
97 UKRI Open Access Review
98 UKRI Delivery Plan 2019 p22
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introducing a new strategic oversight, and in gaining the support of the wide range of 
stakeholders, including the public, with whom UKRI will interact. The overall success 
of UKRI is dependent on overcoming these challenges at an early stage.
63. We recognise the complexity of addressing the balance of funding of the dual 
support system and that this is a fundamental remit of UKRI. Creating a robust 
evidence base for this assessment will be crucial, and we recognise that UKRI strategy 
is to approach the task cautiously and without any sudden shifts in funding.
64. In line with the approach taken in this Report, UKRI should also assess and report 
on other dimensions of balance such as the regional concentration of funding, the 
balance between research and innovation, and the balance between capital and current 
spending, in a similar manner to its analysis of the dual support system. We believe 
more immediate changes to funding are appropriate to influence the current balance in 
these areas. There are many possible ‘balances’ or policy mixes, and this political choice 
should be transparently set out.
Evaluation
65. The UKRI Strategic Prospectus outlined the ambition to build a culture of evaluation 
at UKRI.99 The creation of UKRI is intended to build on “existing strengths” in order to 
use data “in new ways to look across the research and innovation landscape to understand 
the impact of our investments and maximise the return we get”.100 This also recognised 
that evaluation of the return on investment was “notoriously difficult”, due to “long lags, 
difficulties in obtaining a true baseline, and difficulties in correctly attributing benefits”. 
Evaluation is both internal, through a “framework for tracking and reporting UKRI 
performance” that will also have a focus on “specific areas of strategic importance such as 
Place, Talent, and Infrastructure”; and also outward-facing where to measure performance 
against long-term ambitions UKRI will “monitor a broad set of outcomes with a wide 
range of quantitative and qualitative indicators”.101 These include:
• Pushing the frontiers of human knowledge and understanding: New research 
tools, and methods; high quality people; and improved knowledge sharing;
• Delivering economic impact: New products, businesses and services; increased 
business growth and jobs; links between the research and the innovation, 
business and investment communities; and
• Creating social and cultural impact: Improved wellbeing; health outcomes; 
improved policymaking and public services; improved security, resilience, and 
cost avoidance.
66. UKRI reiterated its commitment to undertaking this robust monitoring and 
evaluation,102 drawing attention to previous evaluations of Knowledge Transfer 
Partnerships103 and the Small Business Research Initiative.104
99 UKRI Strategic Prospectus p28
100 UKRI Strategic Prospectus p28
101 UKRI Strategic Prospectus p44
102 UK Research and Innovation (BER0063) para 25
103 Innovate UK, The Knowledge Transfer Partnership programme: an impact review, Oct 2015
104 BEIS, Leveraging public procurement to grow the innovation economy; an independent review of the Small 
Business Research Initiative by David Connell, Nov 2017
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67. In evidence the innovation foundation Nesta suggested that there was limited 
evidence on the effectiveness of innovation and growth policy, and without good evidence 
it was impossible to allocate limited resources to the programmes that have the greatest 
impact, whilst also suggesting there was insufficient innovation in these policies to allow 
better analysis.105 This was supported by the Academy of Social Sciences submission, 
highlighting the need for a specific strand of research (“diagnostic, experimental and 
evaluative”) to find out what worked in improving productivity.106
68. Nesta also suggested that traditional data sources, such as business surveys and 
academic publications and patents, were ill-suited for analysis in new industries, failed 
to capture networks of collaboration, and might involve substantial time lags.107 Kirsten 
Bound of Nesta suggested that more should be done to capture the “power and possibility” 
of ‘big data’, for example:
we should look at scraping millions of job ads, to see which technologies 
people are hiring for. We should look at the information in thousands of 
websites and millions of open datasets, draw it together and visualise it in 
new ways, so that policy makers can have much more granular and real-
time access to data for decision making.108
69. In our session with UKRI, Professor Sir Mark Walport agreed that evaluation and 
measurement of success was an “absolutely critical” part of their work, but conceded that 
this was also “very hard”, suggesting that the “initial focus” must look at “what outputs 
from our funding are, both at the level of discoveries and at the level of innovation.”109 The 
then UKRI Director of Strategy, Rebecca Endean, elaborated on the evaluation that UKRI 
had undertaken to date:
As a starting point, UKRI has gathered together all our grant-funding data [ 
… ] on a coherent and consistent basis, so we know which grants are funded. 
We can then collect outputs from those grants, from the monitoring that 
IUK [Innovate UK] does and from how people report on them, through 
their grants and with Researchfish.110 [In order to understand outcomes] 
we need to link that grant data to a range of outcomes in firms. We can look 
at spin-outs, patents and business growth in firms. That allows you to do 
the evaluation consistently at a microeconomic level. You look at what you 
are spending the money on and what that actually leads to.111
70. This approach was replicated in the recently published UKRI delivery plan, where 
it stated that as a near term action UKRI would “continue to develop our data reform 
programme, bringing together key datasets and enhancing our analysis tools and 
capabilities to better capture UKRI’s wider impact.”112 In supplementary evidence UKRI 
highlighted its commitment to “research on research”, such as through the Economic and 
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Social Research Council investment in What Works Centres, which aim to improve the 
way Government and other organisations create, share and use high-quality evidence for 
decision-making.113
71. We support UKRI’s commitment to evaluation, and understand the inherent 
difficulties in analysing the impact of research and innovation and attributing it to 
wider outcomes, which may occur after a significant time-lag. We recognise that in 
some cases evaluation will be impossible and UKRI should be explicit that this is the 
case and explain why. Unfortunately the current focus appears too strongly to follow 
traditional metrics, measuring outputs such as publications and patents that should 
only be one element of evaluation.
72. Research on research is an increasingly important field, and we recommend that 
UKRI consider a dedicated approach to supporting it, including how this research is 
incorporated into UKRI strategy and its assessment of the balance of R&D funding. 
Relatedly, UKRI should attempt to analyse the benefit gained by its creation through 
its enhanced ability to capture data across research councils and through cross-cutting 
funds.
73. We recommend that UKRI also develops a ‘big data’ focus for evaluation. It should 
publish a plan for creating and investing in new data sources and analysis techniques 
beyond traditional measures of patents and publications.
Government influence on research and innovation beyond UKRI
74. Whilst the establishment of UKRI is clearly viewed as an opportunity for increased 
coordination and coherence in R&D spending, albeit with inherent risks, we must also 
be aware of the limitations of its influence. The combined budget of UKRI is around £7 
billion, but as the Campaign for Science and Engineering, a non-profit advocacy body, 
noted “30% of public R&D spend and a disproportionate amount of benefit from research 
and innovation fall outside UKRI and outside BEIS”, meaning that other organisations 
are important too:
Many of the levers that will be needed to improve the environment and 
achieve the R&D target sit in other departments, including Treasury, 
HMRC, International Trade, Home Office, Health, DCMS amongst others. 
Members (of the Campaign for Science and Engineering) have raised with 
us their experience of government actions competing against other parts 
of government creating hinderances and frustrations for businesses and 
diminishing effectiveness of positive government policies, funding and 
initiatives.114
75. The frustrations mentioned demonstrate the complexity of the R&D landscape (see 
paragraph 42), and the difficulty in leveraging private sector R&D which will be crucial in 
reaching the 2.4% R&D target. Whilst there are a multitude of other Government actors 
responsible for both Government spending and control of the policy levers that influence 
private spending, BEIS has a responsibility for coordinating these levers and developing 
113 UK Research and Innovation (BER0098) p1
114 Campaign for Science and Engineering (BER0065)
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the policy mix. Professor Sir Mark Walport suggested that the overall landscape “is 
perhaps more joined up than it appears to be at first sight” but it is “necessarily a complex 
landscape, and I think we could do more”.115
76. These areas form the basis of our analysis in Chapter 5, and include:
• the 30% of R&D funding that is undertaken by Government outside of UKRI;
• harnessing the power of wider Government procurement to stimulate research 
and innovation;
• R&D tax credits as an incentive for private sector investment; and
• the issue of finance (related to the “valley of death” of business development) 
which we address through patient finance.
77. We recognise that there are many other important policy contributions that will 
influence R&D. For example, as Professor Sir Mark Walport stated, “education policy is 
absolutely key”,116 as are place, infrastructure and industry support, which we expect to 
be included in the UKRI and BEIS roadmaps to give a better “holistic sense”117 of these 
other important drivers. Due to the breadth of possible areas we have not addressed all 
of these in this Report and instead have focused on areas where more direct intervention 
was highlighted.
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4 UKRI influence on the balance of R&D 
spending
78. In this Chapter we address the issue of balance in R&D spending across the different 
dimensions we identified through this inquiry. Our focus is on the influence that UKRI 
can exert, and the opportunities created to re-assess existing balances that may be the 
product of previous political decisions or the result of the previous R&D ecosystem. In 
turn we address the balance between: the two elements of the dual support system; regional 
spending; ‘pure’ and ‘applied’ research; research and innovation; different research 
disciplines; capital and current spending; and domestic and overseas policy goals.
UKRI
79. The terms of reference for our inquiry requested evidence regarding the rationale for 
deciding on the balance of public R&D over a range of dimensions, However, whilst much 
of the evidence we received was useful for illuminating the inherent trade-offs, there was 
often very little to suggest the optimum level. As the innovation foundation Nesta stated 
“there are no easy answers to the question of finding the ‘right’ balance of funding.”118 
This was reflected in the response of Professor Sir Mark Walport, Chief Executive of 
UKRI, regarding the issue of investigator-driven research; “It is slightly like asking, ‘How 
long is a piece of string?’ There is no simple right answer to what the balance should be.”119 
The appropriate balance will depend on the goals and objectives of research policy. As 
outlined in Chapter 3, the complexity and uncertainty of the research system may mean 
that the optimal balance is unknowable.
80. Decisions about what balances to strike are essentially political. The current 
balance and concentration of funding is the result of previous policy choices, and 
this should be explicitly recognised. But the various balances discussed in this Report 
should take account of current goals and needs rather than reflecting those of past 
decades.
81. Finding the correct balance in each area may be impossible, but it is the policy 
mix needed to best support R&D that is important rather than just the performance of 
individual policies. Although optimal balance might not be identifiable, in many cases 
where evidence recommended a need for increased funding, such increases might be 
more feasible and palatable in an environment with an increasing spending envelope 
as they will not necessitate reallocation of funding from elsewhere.
The dual support system
82. The “dual support” system is widely regarded to be a key feature of UK research 
funding. Through this combined approach, research councils (RCs) offer competitive 
project-based funding, whilst Quality-Related (QR) block funding based on quality 
assessment through the Research Excellence Framework (REF), gives greater flexibility 
for use and longer (seven year) periods of assured funding. As the QR funding is un-
118 Nesta (BER0072)
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hypothecated, universities are free to direct it as they wish rather than specifically to the 
research area for which its ‘excellence’ is awarded, thus allowing cross-subsidisation in to 
other research areas.
83. The balance of these elements has changed over time, with increasing research 
council funding from 2012 not met with increased QR funding. QR funding saw a 13% 
fall in its value in real terms from 2010–11 to 2017–18.120 Until 2015–16, total QR funding 
was higher than research council grant funding to higher education institutions, but is 
now slightly lower.121
84. Most university submissions, including the UCL and Coventry University submissions, 
supported a continuation of QR funding, and many had concerns about the level of QR 
given its relative reduction in recent years.122 Universities UK stated that “in recent years, 
QR funding in England has remained at a flat level. Given the importance of such funding 
to the UK research base, the UK Government should raise levels of investment in QR while 
considering the impact on devolved nations.”123 Professor Reid of UCL agreed with this 
sentiment whilst extolling the benefits of QR, including increased agility, stable careers for 
researchers, and ability to meet the full economic costs of project funding.124
85. Gordon McKenzie (CEO of GuildHE, a representative body for UK higher education) 
stated that QR was more equitable from the perspective of smaller institutions and 
research environments, as many small institutions received no research council funding 
at all.125 But the seven-year REF cycle also created limitations and “may need to be 
tweaked, because smaller research environments grow quickly from a relatively low base”. 
Mr McKenzie told us that it would be beneficial to find a way to feed money in to continue 
building capacity in these areas in between the REF cycles.126 The GuildHE submission 
suggested the following process:
a year on year uplift of QR, via a ‘gearing’ formula providing at maximum 
10% increase in funding, for institutions with relatively low QR allocations 
- say, below £200,000. This would be expressly to support emerging research 
environments to establish infrastructure and capacity to keep pace with 
mandates and enable them to more effectively enter competitive schemes.
[ … ] such investment would need to be monitored to ensure the additional 
funds are used for expressed purposes. We suggest institutions provide 
strategies for the additional investments, and also provide monitoring data 
at reasonable intervals. This has a precedent - allocations for GCRF [Grand 
Challenge Research Fund] within QR is handled in a similar way.127
86. The suggestion of further assessment for QR was countered by Professor Reid of UCL 
though, who suggested that “we should recognise the stability of the long-run REF cycle 
combined with more dynamic grant awards”.128
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87. None of the evidence specified what the balance between QR and project funding 
should be. Professor Reid said he could not point to “evidence that will determine the 
balance of project funding and QR funding”.129 Professor Sir Mark Walport agreed that 
understanding the balance between the two elements was work in progress.130
88. Following our evidence sessions, in an announcement on 2 July 2019, Research 
England published budgets for university research for the year 2019–20. This included 
an additional investment of £91 million, of which £45 million was to be allocated to 
mainstream QR funding, an increase from £1,050 million in 2018–19 to £1,095 million in 
2019–20.131 The former Minister commented on the announcement that:
for the first time since 2010, we have a significant uplift in QR funding 
for universities [… which] marks an important recognition of university 
research and the need to invest more in flexible, curiosity-driven research 
that has tremendous benefits to developing our international standing as a 
research powerhouse.132
89. We recognise that the dual funding system of block grants and project-based 
research council funding has been crucial to the success of UK universities, and that 
maintaining this system with ‘appropriate balance’ will be a key function of UKRI. 
There may be no optimal balance, but trying to reach an appropriate balance in the light 
of current policy goals is a key political choice and should be made in a transparent and 
accountable fashion. UKRI should continually monitor the appropriateness of balances 
struck in the operation of the dual support system and publish the advice given to the 
Government, alongside its analysis and commentary, at regular intervals.
90. The flat profile of QR funding in recent years suggests it has not been prioritised 
in funding decisions. The announcement of a £45 million increase in mainstream QR 
funding by Research England in July 2019 indicates that there may be a change in 
this focus, and a recognition of the benefits of un-hypothecated budgets which allow 
universities to maintain agility and develop their own areas of expertise. We recommend 
that focus on QR funding is maintained in future considerations, and that QR should 
continue to be prioritised to address previous real-terms reductions in funding.
91. UKRI should review the quality-related (QR) formula which has been responsible 
for increasing concentration of regional spending, paying attention to the formula used 
in Scotland which has been less geared towards driving concentration.
92. Whilst QR funding provides a stability of funding over the course of the seven-
year REF cycle, we also recognise that these timeframes create barriers for smaller 
but potentially fast-growing institutions or areas of excellence who receive lower QR 
allocations. We recommend that in UKRI’s ongoing evaluation work it reviews whether 
additional support for these institutions should be provided, possibly through specific 
gearing of investment across the REF period, through additional review periods for 
smaller bodies, or through separate QR stream for smaller and specialist institutions.
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Regional concentration of research
93. We received a great deal of analysis regarding the concentration of research funding. 
This clearly supported an understanding of the ‘golden triangle’ of concentration of 
funding in universities in London, Cambridge and Oxford. Eurostat data shows that 41% 
of Government-supported research was concentrated in these three regions (Inner West 
London, Oxford, and Cambridge).133 Royal Society analysis, based on ONS data, shows 
that London, the South East and the East of England accounted for 42% of UK R&D 
funding.134
94. We understand that it is possible to paint a different picture, as normalising for 
regional population, gross value added, university concentration, and the split between 
public and private spending can all give a different interpretation of concentration and 
research funding prioritisation.135 However, this argument was more forcefully made 
by institutions that had to date benefited from previous regional concentration; the 
Russell Group concluded that “whilst there are clear differences between the regions, the 
expenditure figures alone do not give us a full overview of what is a much more complex 
picture”.136 UCL agreed that any assessment of geographic distribution required the scale 
and characteristics of the region to be taken in to account and that there was no “uniquely 
authoritative” way of describing this distribution.137
95. Whilst the pattern can be analysed in different ways it seems clear that there is a 
concentration of research in the ‘golden triangle’, largely driven by the ‘Excellence Principle’ 
of a funding allocation based on assessed research excellence, further accentuating any 
natural ‘Matthew Effect’—essentially that as any cluster grows it becomes more likely to 
be successful in securing funding, leading to further growth.138 Professors Wilsdon and 
Jones of the University of Sheffield argued that any ‘place-blind’ funding would eventually 
lead to this effect, but that this meant ‘place-blind’ was not the same as ‘place-neutral’,139 
thus again reflecting a deliberate political policy choice in terms of regional concentration.
96. This regional agglomeration has been long-recognised, with a predecessor Committee 
of ours noting the difficulty created by the Excellence Principle and the funding 
concentration in the golden triangle:
On the face of it, the Excellence Principle is a good thing because it keeps 
science competitive and sends the money where it is most likely to produce the 
best results. However, there is a clash with another very important concept. 
The Government views science and innovation as key factors in economic 
development. This is a long-standing position that has been reaffirmed 
many times since the current economic crisis started. When one combines 
the view that science and engineering are important for the economic 
health of a region, on the one hand, with Government’s responsibility for 
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the economic health of the region, on the other, one logically arrives at a 
policy whereby the Government makes strategic decisions regarding the 
economic health of regions by influencing where research money is spent.140
97. Both Professor Sir Mark Walport of UKRI and the then Minister recognised these 
tensions between the rewards for excellence increasing regional redistribution, but 
stressed that the excellence of institutions should not be diminished.141 They raised several 
points regarding the possible policy response. The then Minister highlighted the current 
policies aimed at addressing regional imbalance, including the Strength in Places Fund, 
the Northern Powerhouse strategies for future investment, and a longer-term strategy of 
investing in people, ensuring that there was a supply chain behind larger infrastructure 
projects.142 Professor Sir Mark Walport echoed this last point in his analysis of what was 
required to create new clusters of excellence:143
If you look at the four features of a cluster, first and foremost it is about 
leadership. It is very difficult to develop clusters if there are not strong 
leaders. The second is an area of business strength; thirdly, it is a combination 
typically of universities that can provide the range of skills needed; and, 
fourthly, it is local support. That is what we are looking for in the strength 
in places fund. If we are going to grow the economy in other parts, that is 
what we have to be looking for.144
98. The then Minister was clear that he did not want the Strength in Places Fund 
(SIPF) to be viewed as the only “magic-bullet” solution to the regional issue, and that it 
needed to sit within other policies such as the Higher Education Innovation Fund and 
the progression of the Industrial Strategy.145 Encouragingly the responses we received 
were supportive of the SIPF.146 For example, the Academy of Medical Sciences called it 
“a positive step towards the goal” of increased investment in research and innovation 
across the regions. However, there were also suggestions that a larger fund would be more 
effective.147 Professor Wilsdon of the University of Sheffield, for example, suggested that 
to tackle the balance issue at a regional level it would need to be “larger by an order of 
magnitude to make a significant difference”:148
The Strength in Places Fund is very welcome. It is not sufficient to tackle the 
scale of the regional imbalances in R&D spending [ … ] this is a debate that 
needs to be approached with nuance and subtlety. It is not simply a matter of 
“out of the golden triangle good, inside bad.” However, there are observable 
trends towards greater concentration over the last 20 years. They are very 
clearly visible in the data. There are also all of the dynamics we have already 
touched on within the system that will further concentrate R&D spending 
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in areas that are already successful … . [E]xcellence breeding excellence. It 
is also other Matthew effects… in the funding systems. It is very hard to 
disentangle the positives from the negatives of all of that.149
99. Evaluation of the SIPF is likely to prove difficult. We have already identified some of 
the issues regarding the measurement of regional concentration of funding (paragraph 
94) that mean at an input level there may conflicting considerations. The diversity of goals 
that might be addressed by regional R&D and innovation activity further complicates 
matters, and in terms of outcomes, measuring the influence of any policy on local 
economic growth is innately complex.150
100. Place is a key focus within both the Industrial Strategy and the UKRI strategic 
prospectus and development plan. In the context of the regional concentration of 
research funding, the aim should be to build further research excellence outside of its 
existing predominance in the South East of England. We strongly agree that additional 
regional funding should not be to the detriment of this ‘golden triangle’, and excellence 
in this area should continue to be rewarded, recognising that this is a tide that lifts all 
boats in terms of international recognition of the UK as a place of quality research. 
However, in order to contribute to the 2.4% R&D target, regional strengths will need 
to be harnessed and cultivated.
101. For wider regional growth to succeed, expertise and infrastructure beyond 
universities will be required, as envisaged in the wider Industrial Strategy. For UKRI, 
the main lever with which to stimulate regional excellence is through the Strength 
in Places Fund (SIPF). The SIPF is still in its infancy, but its rationale and its goals 
remain somewhat opaque and it is too modest to drive any significant rebalancing of 
investment given the strength of existing drivers of increasing regional concentration 
in funding. Whilst the fund is still in its infancy, it appears to be a more innovation-
orientated approach that appears too small to drive a significant re-balancing of 
investment given the current level of regional concentration in funding.
102. We recommend that UKRI and BEIS substantially increase the size of the Strength 
in Places Fund given it appears to be the primary lever through which it is attempting 
to influence the regional concentration of funding and create new centres of excellence 
beyond the golden triangle. It should further clarify the rationale and expectations of 
this expanded programme. This should include the intended evaluation approach and 
key metrics for assessing the level of regional concentration of funding and the outcomes 
of this funding.
Balance between ‘pure’ and ‘applied’ research
103. Our call for evidence asked respondents to explain the rationale for allocating 
funding between the ‘pure’151 and ‘applied’152 elements of research. Evidence received 
suggested that such definitions were contentious, with BEIS suggesting that this is “an 
artificial construct with a blurred boundary”.153 Partly reflecting this view, evidence 
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submitted to the inquiry also used a range of different terminology for both ‘pure’154 and 
‘applied’155 research. The OECD Frascati manual definitions do refer to ‘basic research’ 
‘applied research’ and ‘experimental development’, and these categories are widely used 
for statistical purposes.156 For the purposes of our inquiry we have continued to use ‘pure’ 
research, but consider this synonymous with ‘basic’ research.
104. Much of the evidence received suggested that support for basic research enabled 
future applications which cannot be envisaged. The Royal Society of Chemistry stated:
Support for fundamental, curiosity-driven research must be sustained, 
alongside challenge-based and applied research. Evidence shows that 
supporting fundamental, curiosity-driven research results in long-term 
impacts that bring benefits beyond pushing the frontiers of science–
delivering economic growth and solutions to challenges that the world faces 
with regards to health, energy and environmental sustainability.157
105. Much of the evidence submitted to our inquiry supported the idea of ‘pipeline’ of 
discovery, for which well-funded basic research is required.158 However, we also appreciate 
that most researchers would understandably prefer to be given complete freedom and 
open-ended funding for their work. This pipeline description is also contested by academic 
literature such as the research of Salter and Martin,159 which suggested that the benefits 
of basic research funding was to increase the stock of human knowledge and support a 
creative environment that attracted the top researchers. The new knowledge, equipment 
and methods developed are available to applied and industrial researchers and provide 
the main environment in which researchers were trained. Research results might also 
sometimes inspire applied research or spin outs, but this was probably the least frequent 
or important impact. There are also many historic examples of fundamental insights 
achieved from applied (problem-oriented) research, such as Pasteur’s germ theory.160
106. This would not necessarily imply that there is a need to prioritise basic (investigator-
driven) research. BEIS suggested that, if there were an optimum balance, “it might 
exist where the UK is at the forefront of producing new ideas and has the capability 
to translate these into social and economic benefit to the UK.”161 The Royal Society of 
Biology suggested that “the interdependence of pure and applied research is such that they 
complement each other and this is just one of the reasons to safeguard a healthy balance 
of funding for both”,162 whilst UKRI stated its position that “fundamental and applied 
research, and innovation are often mutually reinforcing element’s of UKRI’s portfolio. We 
aim to recognise their complementarity and break down barriers between them.”163
107. We understand that the distinction between pure and applied research is 
a contested definition and as such it does not appear to be a dimension of balance 
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on which funding decisions can usefully be made, whilst also understanding the 
importance of maintaining funding for pure research as a foundation of other benefits 
and dimensions of balance.
Balance between research and innovation
108. The contested distinction between ‘pure’ and ‘applied’ research noted above 
somewhat extends to that between research and innovation, with much of the latter being 
indistinguishable from highly applied research and what the OECD Frascati Manual 
defines as ‘experimental development’. Though historically the UK has been active in 
taxpayer support for technological development, since the 1980s the decision of Prime 
Minister Margaret Thatcher to end most Government support for so-called ‘near market’ 
research, the UK has had an internationally unusual public research system focused on 
the ‘basic’ research funding through the dual support system.164
109. The UK has generally had a ratio of around 10:1 between science funding and 
innovation funding,165 compared to ratios of “up to 1:1” in other competitor nations.166 
This ratio is largely reflected in the relative budget of Innovate UK compared to the other 
research councils. Evidence from the Catapult Network and AIRTO Ltd suggested that the 
ratio would have narrowed somewhat since the establishment of the Industrial Strategy 
Challenge Fund. The Catapult Network explained:
We would not suggest that there should be an even balance, nor would 
we advocate moving the funding away from research but, at a time when 
private sector confidence to invest is under pressure, we see a compelling 
case for directing increases in public funding to incentivise activity at 
higher [Technology-Readiness Levels].167
However, the submission stated that it was “not making a case for further increases to 
Catapult core grant funding at this time”, instead it was advocating increases in measures to 
support access to finance such as innovation loans, Innovate UK’s Investment Accelerator 
and initiatives to improve the availability of patient capital.168
110. Addressing this issue of balance, Professor Sir Mark Walport stated that “historically, 
the balance was very strongly towards discovery, with very little money spent on the 
innovation side of the fence. Indeed, Innovate UK is only 12 years old this year. It is a 
relatively new agency.”169 The then Minister said that when it:
comes to innovation spending, I think we still have significantly more to 
do [ … ] The question is whether we continue the traditional pattern of 
what we have done, which is to invent and realise significant milestones in 
science and innovation in technologies and let some other country take the 
commercial opportunities.170
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111. Since the 1980s the UK has had a very different profile of scientific research 
spending versus technological development and innovation spending to other 
developed countries. As a result the public sector science base, and the dual support 
system, have been expected to do almost all the heavy lifting of driving and supporting 
innovation, together with an emphasis on commercialisation of academic science. This 
generic science-based innovation policy may explain the paradox that the research 
focused UK system has felt progressively more ‘applied’ and directed to many of the 
researchers working within it.
112. Since the global financial crisis successive Governments have made tentative steps 
back towards more active support for technological development, with milestones 
including the establishment of Innovate UK and the Catapult Network. The Industrial 
Strategy and the Industrial Strategy Challenge Fund are the latest milestones in this 
direction of travel. Funding for the development of new technologies is not the only way 
Governments support innovation, but is an important part of any Industrial Strategy. 
Continued growth in technological development and innovation funding should also 
allow a rethinking of the ‘innovation focus’ of the ‘basic’ public sector science base.
Balance between research disciplines
113. The balance between research disciplines was widely viewed through the balance 
of funding allocation between research councils. QR funding allocated by universities 
themselves can alter this balance, but UKRI does not have discretion over these decisions. 
However, cross-cutting funds administered by UKRI such as the Industrial Strategy 
Challenge Fund and the Strength in Places Fund, and multi-disciplinary collaborations, 
can also influence the balance.
114. As with regional concentration of research spending it seemed that disciplines or 
specific areas of research could become self-reinforcing areas of spending. Research by 
Professors James Wilsdon and Richard Jones highlighted this effect in The Biomedical 
Bubble, suggesting that previous success in the area had created ongoing spending 
commitments that could not be rationalised through cost-benefit analysis.171 At a more 
macro level, Sir Paul Nurse pointed to the Medical Research Council and Natural 
Environment Research Council, suggesting that their proportion of funding had been 
largely unchanged in nearly fifty years: “that tells us that history is determining what is 
happening. That cannot be right”,172 a view supported by Professor Wilsdon.173 Sir Paul 
Nurse’s suggestion was that as funding was increased there should be some cross-research 
council bidding.174 This partly echoed the suggestions contained in his review of research 
councils, one of the key recommendations of which was:
establishing mechanisms to deal with cross-cutting issues such as the 
support of multi-disciplinary and inter-disciplinary research, grand 
challenges and the redistribution of resource between Research Councils 
in response to new developments, advances and priorities in the research 
endeavour.175
171 Nesta, The Biomedical Bubble, July 2018
172 Q24
173 Q21
174 Q24
175 BEIS, Ensuring a successful research endeavour: review of the UK research councils by Paul Nurse, November 
2015, p26
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115. The Strategic Priorities Fund (SPF) built on the Sir Paul Nurse vision of a “common 
fund” to address these issues, an approach that was broadly welcomed in evidence, 
including by the Academy of Medical Sciences and the Academy of Social Sciences,176 
although this was largely in theory as further details were awaited.177 However, Professor 
Dame Athene Donald, Chair of the Interdisciplinary Advisory Panel for REF2021, raised 
significant concerns over the fund, suggesting that the process for allocating funding had 
been:
(a) driven by individual research councils, which raises all the pre-UKRI 
concerns about work that straddles boundaries and accompanying concerns 
about how assessment will be done;
b) is unlikely to provide a means by which genuinely exciting cross-cutting 
research gets promoted and fairly assessed;
c) carried out with a total lack of transparency raising the spectre that 
one of the key roles that UKRI might play is being lost without a genuine 
discussion of the funding balance ever being initiated.178
116. Wave 1 of the SPF has subsequently been announced by UKRI and detailed in the 
delivery plan, with UKRI committing to deliver the SPF programmes announced to 
date, including running research calls and innovation competitions open to researchers 
and business across the UK.179 The updated documentation does not clearly address the 
concerns raised by Dame Athene. Whilst UKRI was very supportive of the fund during 
our evidence session, the commitments to being “agile and responsive to exciting new 
opportunities” and examples of funding such as modern anti-slavery research at the Arts 
and Humanities Research Council failed to address these criticisms.180
117. The balance across research disciplines should be easier to monitor and adjust 
under UKRI. Historic patterns clearly should not be maintained for their own sake. 
However, we are concerned that the Strategic Priorities Fund (SPF) may have not been 
established in a way that effectively addresses this issue. We recommend that UKRI 
review the SPF and ensure that individual research councils are not exerting excessive 
influence on what is intended to be a cross-council, multi-disciplinary focus.
118. Future consideration of the balance between disciplines must include robust 
evaluation of research areas within each discipline. We find the case regarding 
entrenched concentration of research analysed in The Biomedical Bubble compelling. 
UKRI analysis should widen this approach and conduct relevant cost-benefit analysis 
of larger research areas within different disciplines to establish whether R&D spending 
remains productive.
176 Academy of Social Sciences (BER0034) para 1, Academy of Medical Sciences (BER0069) para 19, Royal Society of 
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Balance between capital and current funding
119. Evidence submitted to the inquiry specifically citing the level of capital expenditure 
was relatively limited. A previous review of capital funding by the Higher Education 
Funding Council for England (HEFCE, the precursor to Research England), showed that 
funding for capital expenditure had reduced by nearly 70% between 2005–06 and 2013–14, 
from £1.2 billion to £340 million.181 Evidence from the Institute for Cancer Research (ICR) 
noted that capital funding had remained at a similar level since 2013–14, representing a 
real-terms decrease.182 The ICR also noted that other sources of research funding had 
grown at a faster rate than core funding for infrastructure, and that given that project 
grants did not cover the overheads of research, there was not enough investment in the 
physical infrastructure of higher education institutions, including research equipment, to 
keep pace with project funding.183 This is likely to be reflected in the concerns regarding 
the Full Economic Costs (FEC) of research that were also highlighted in our evidence 
sessions.184
120. The Earlham Institute suggested there was a need for better coordination between 
capital and resource funding awards:
At times, capital funding is awarded for the purchase of new equipment, 
such as DNA synthesisers and high-performance computing equipment, 
but the budget for the required software, training, staff and electricity to 
run the equipment have to be paid from revenue awards that are fixed across 
budget cycles. The situation is not practical or efficient, impairs research 
impact and even causes delays to research.185
121. This represented what the Association of Innovation, Research and Technology 
Organisations (AIRTO Ltd) referred to as the ‘batteries not included’ scenario 
investment:186 facilities or major items of research equipment were made without ongoing 
resource spending commitments in place. Ongoing costs are not guaranteed but expected 
to be covered be the normal functioning of the dual support system, i.e. through QR 
and competitively won grant funding. This represented a “very ineffective use of public 
funding”.187
122. UKRI was commissioned by BEIS in January 2018 to develop the first national 
research and innovation infrastructure roadmap,188 which sought to detail existing UK 
infrastructure, future needs, and resulting investment priorities. The most recent Progress 
Report was published in March 2019, identifying emerging themes and areas of potential 
capability that could be addressed by new infrastructures (identified through consultation 
with research and innovation communities).189 This is an important exercise which should 
be beneficial in setting out new infrastructure plans over the next 10 years. The roadmap 
was supported by Professor Dowling of the Royal Academy of Engineers, Professor Hall 
of the Earlham Institute and Dr Griffiths of the Institute for Cancer Research, although 
181 Frontier Economics, A review of HEFCE capital expenditure, 2015 p8
182 The Institute of Cancer Research (BER0086) p2
183 The Institute of Cancer Research (BER0025) p2
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Professor Hall noted “it is being put together very quickly, which is worrying, in a way.”190 
It appears likely that new UKRI funding, such as the Strength In Places Fund and the 
Strategic Priorities Fund, will also put in place new infrastructure, which may exacerbate 
issues regarding future resource funding. However, it is not obvious from the infrastructure 
roadmap that the relationship between capital funding and resource spending is being 
addressed.
123. We welcome the opportunity to redress reductions in capital investment for 
research. The UKRI roadmap represents an opportunity to consider where investment 
can be focused and most effective in contributing to ongoing research excellence and to 
the wider goals of the 2.4% target. In order for UKRI to take ownership of the ‘batteries 
not included’ issue, we recommend that decisions for investment include consideration 
of the coordination of capital and revenue funding and the long-term requirements of 
new and existing investments. Major capital investment project plans should explicitly 
state assumptions regarding future QR or research council funding that may be required 
to staff or run them.
Balance between domestic and overseas policy goals
124. Through the establishment of the UKRI-administered Global Challenges Research 
Fund and the Newton Fund (both described in the previous Chapter), UKRI claims to 
demonstrate the belief in the “importance of research and innovation to address global 
challenges and promote global economic development”.191
125. Organisations such as the Royal Academy of Engineering expressed support for 
this stance, agreeing with the importance of the UK taking the lead in addressing global 
challenges such as access to clean water.192 Universities UK also suggested that they 
represented “long-term investments, the benefits of which will not be realised in the short-
term. It is therefore important that such schemes are maintained.”193
126. However, the Russell Group suggested that funding sources tied to Overseas 
Development Assistance (ODA) had a similar effect to those of the National Productivity 
and Investment Fund, ring-fencing too much of the funding available to universities.194 
They suggested that the proportion of funding related to these schemes increased from 
10% in 2017–18 to 19% in 2019–20. Excluding these funds, the core budget of five of the 
nine research councils would decline.195 They also suggested that this would have an 
impact on the councils’ ability to fund core activities, including responsive mode funding 
and post graduate research training.196
127. There are concerns that ring-fencing of funds for specific goals such as overseas 
development assistance will further diminish the ability of universities to undertake 
responsive mode funding. This is related to wider concerns regarding quality-related 
funding and the implications for basic research from a perceived focus on application-
led research. Whilst we do not currently see this as a pressing concern, UKRI should 
continue to monitor this balance and detail the proportion of ring-fenced funding on 
ODA in its publications.
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5 Beyond UKRI—wider balance
128. UKRI investment in research and innovation will be a cornerstone of total R&D 
spending in the UK. However, there are other significant roles played by the Government. 
Departments other than UKRI are also responsible for innovation support and direct 
R&D spending, and there is wider public procurement that might drive innovation. 
Giving more emphasis to increasing demand for innovation by encouraging customer (i.e. 
Government) funding, rather than focusing on ‘technology push’ from university research, 
represents a potential shift in policy focus.197 The Government also has a supportive role 
shaping the wider investment landscape, through rules and incentives that encourage 
firms to invest and undertake innovative practices. In this Chapter we explore the role for 
coordinating innovation across Government, specific support through the Small Business 
Research Initiative and other public procurement, financial incentives such as R&D tax 
credits, and regulation of longer-term investments or patient capital.
Wider support for innovation across Government
129. In both written and oral evidence the Campaign for Science and Engineering (CaSE) 
drew our attention to work they had undertaken cataloguing a list of Government backed 
sites or webpages detailing innovation support.198 They suggested that whilst “there is a lot 
of good innovation support, infrastructure and incentives in the UK [ … ] the UK does 
not effectively showcase or communicate the UK offer domestically or internationally.”199 
This led to the recommendation that a ‘one-stop shop’ be created to gather this information 
from across Government:
Government [should] create a digital ‘shop window’ that showcases in 
one place the many different incentives, funding, and initiatives for UK 
research and innovation support, providing sufficient resource for it to be 
maintained. This one link could then be easily shared to direct people to 
the array of support available. This is not just a communications challenge, 
but also should spur functional improvement and join up across different 
parts of national and local government systems, messages, portals and 
opportunities. This could be an opportunity to use SBRI to procure an 
innovative solution to the challenge.200
130. It is further recommended that this be part of a wider work programme to clarify and 
effectively communicate the UK offer at the top level, using differentiated and targeted 
communications to reach key audiences.201 Whilst efficient firms may not struggle to 
navigate these alternative finance and support routes, it seemed likely that the additional 
complications would disproportionately affect and disincentivise small and medium 
enterprises.
197 Mr David Connell (BER0006)
198 Campaign for Science and Engineering, What Government support is available for research and innovation?, 
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131. When this was raised with the then Minister, he agreed that there might be a possibility 
of creating a “more effective one-stop shop”.202 Following our evidence sessions, the CBI 
also stated support for a “digital one-stop shop” outlining the range of innovation support 
that business can access.203
132. There are a myriad of funding sources for research and innovation, many of them 
provided by UKRI. However, Government departments outside of UKRI, notably 
the NHS and the Ministry of Defence, invest a significant amount in R&D. The 
Government needs to make it as easy as possible for businesses to locate and access 
these opportunities.
133. The Government should conduct a review of all the funding streams and 
opportunities for R&D support advertised across Government. It should create a central 
linking point or web portal for access, and consider how this is advertised, particularly 
to SMEs.
Existing Government demand for R&D
134. Latest ONS data for 2017 shows that the UK Government’s expenditure on science, 
engineering and technology (SET) relating to research and development was £12.2 billion 
in 2017, representing 0.59% of GDP.204 Within this, civil departments represented 30% 
and the Ministry of Defence 13%.205 Dr Sarah Main of CaSE summarised this when 
saying “we know that UKRI is responsible for about 70% of public R&D spend. Other 
Government Departments are responsible for the other 30%. Defence and the NHS are 
significant players in that, but many Departments are responsible.”206
135. The importance of this investment had been recognised previously. The NAO’s 
analysis of cross-Government funding of R&D in 2017, for example, recommended that 
BEIS begin work on identifying areas of research that needed strategic leadership and 
co-ordination,207 and elements of this appear to have informed the Industrial Strategy 
through the ‘Grand Challenges’ and Challenge Funds. But departments will continue 
to undertake their own investment and this should not be overlooked in the systematic 
approach the Government should be taking to reach its R&D target. BEIS director Jenny 
Dibden recognised this but also suggested that the creation of UKRI provided a greater 
opportunity for coordination, saying it was:
absolutely right that other Departments have them, but there is something 
about the creation of UKRI and the fact that Innovate delivers on its behalf, 
which means you can begin to get more coherence, and that is absolutely a 
question we are looking at as part of the 2.4% road map.208
136. The Government strategy for reaching 2.4% R&D investment, which we hope will 
be illustrated in the promised roadmap, should highlight the cross-Government R&D 
investment that is undertaken, particularly by large departments such as the NHS 
202 Q464 [Chris Skidmore]
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and Defence. The roadmap should include detail on UKRI’s role in coordinating this 
investment. The creation of UKRI represents an opportunity for it to operate as the 
ultimate steward of this system.
137. While departments should be free to invest in areas of individual importance, 
UKRI should maintain a strategic overview of potential synergies with UKRI funding 
and the impact on skills and infrastructure that this creates. It should also analyse the 
potential impact of this cross-Government funding on dimensions of balance such as 
regional concentration of spending that we have addressed in this inquiry.
The Small Business Research Initiative (SBRI)
138. Whilst the Government should not overlook the existing demand for innovation by 
departments discussed in the previous section, there are additional mechanisms through 
which demand for innovation could be stimulated. The main example identified in our 
inquiry was the SBRI, a programme aimed at helping small businesses take advantage of 
procurement contracts that the Government is offering, helping innovators to demonstrate 
and develop their new technologies and Government organisations to solve challenges by 
connecting them with innovative businesses.209
139. The Dowling Review singled out SBRI as an important mechanism for encouraging 
collaboration,210 and this was endorsed by the Government’s response to the Dowling 
Review in 2016.211 However, David Connell led an independent review of SBRI that 
reported in November 2017, which found that these endorsements were not reflected 
in practice.212 The use and method of implementation of SBRI varied widely across 
Government, highlighted by the fact that in 2015–16 funding through the scheme fell 
to only £63 million, a 25% reduction compared to the previous year’s peak. The review 
made several recommendations on how to make better use of the opportunity presented 
by SBRI, including:
• the establishment of a central SBRI fund into which public sector organisations 
could bid to fund a programme of SBRI competitions, to reach around £250m 
per annum within six years;
• the establishment of a ‘National SBRI Fund Board’, comprising public and 
private sector representatives, to oversee the central SBRI fund, set funding 
conditions and guidelines for SBRI programmes and review departmental or 
agency programme proposals; and
• the introduction of a third phase of funding for a small number of projects, 
combined with a drive to ensure that funding for first and second phase projects 
meet guidelines (£50,000–100,000 for Phase 1 and £250,000–1m for Phase 2).213
209 The SBRI (delivered by Innovate UK) is a two-stage, contract-based programme to fund the development of 
innovative technology solutions to meet government needs - either for departments’ own requirements or to 
meet policy challenges. Phase 1 contracts are worth £50–100,00 and Phase 2 £250,000 to £1 million, with project 
costs 100% funded.
210 BEIS Dowling Review of Business-University Research Collaborations July 2015, recommendation 29
211 BEIS Response to the Dowling Review of business-university research collaborations Dec 2016
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140. The main Government response to the recommendations has been the creation of 
the GovTech Catalyst Fund, designed to “incentivise Britain’s tech firms to come up with 
innovative solutions to improve public services”; it currently has four challenges, including 
tracking waste and cutting traffic congestion.214
141. This fund is significantly smaller than the Connell Review recommendations, 
standing at only £20 million. Professor Sir Mark Walport noted that “skills to procure 
innovation through SBRI are a scarce commodity, unfortunately”, although through 
things like the GovTech Catalyst fund, “the Government are exploring ways to expand 
it”.215 Jenny Dibden of BEIS agreed that “it is small, but it demonstrates to people that it 
can work. There has been a huge amount of interest from a whole range of public sector 
organisations in receiving this money”.216 The then Minister agreed that the GovTech 
fund was essentially “testing the recommendation for a central fund”.217
142. We have previously addressed these issues in our Quantum Technologies Report.218 
We now re-iterate those conclusions, as follows.
143. We agree with the Connell Review that the Small Business Research Initiative has 
a “unique and valuable role to play in the innovation and procurement landscape”, 
supporting UK businesses in developing innovative new products while enabling public 
sector bodies to source innovative solutions to the challenges they face. However, the 
Government’s response to the Connell Review so far is limited.
144. The GovTech Catalyst only supports public bodies in sourcing digital technology 
solutions and the three-year, £20m GovTech Fund is significantly smaller than the 
£250m that the Connell Review recommended to be spent per annum through SBRI, 
or the £200m target the Government had for SBRI spending in 2014–15, and should 
not be viewed as a replacement. We recommend that the Government fully adopts the 
recommendations of the Connell Review, and establishes a central SBRI fund with a 
National Board to oversee its delivery as part of the 2020 Spending Review.
145. The Government should consider using the SBRI to procure the web portal for 
innovation support detailed in the recommendation at paragraph 133, allowing external 
experts and potential users to create an intuitive directory and system for coordinating 
future innovation support schemes.
Public procurement
146. The SBRI is potentially an important tool, but as the Royal Academy of Engineering 
(RAEng) said, “it is important not to reduce public procurement to SBRI: procurement 
can be used beyond research and beyond small businesses”.219 The RAEng pointed to 
MoD projects and the Highways England Innovation Fund as important examples of 
procurement beyond SBRI.220
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147. The Industrial Strategy Green Paper highlighted that the public sector as a whole 
spent around £268 billion per year on procurement, equivalent to around 14% of GDP.221 
The CBI agreed that this was an “important lever” for driving innovation and that with 
“government being such a powerful buyer in the UK economy, its actions can stimulate 
demand for new technologies, creating marketplaces that induce the development of 
innovative new products and services.”222 How to make this public procurement more 
‘innovation-friendly’ was a key challenge, and the diversity of procurement opportunities 
might be glossed over in the search for one-size-fits-all models.223
148. However, the CBI surveys showed that only 5% of businesses agreed that current 
public procurement processes in the UK incentivised innovation. This was supported 
by RAEng who were concerned that whilst procurement had the potential to have a 
“disproportionately transformative effect on UK companies”, procurement processes 
were a “significant barrier to increased R&D investment” due to the “focus on achieving 
the lowest cost, failure to develop collaborative relationships, restrictive rules on IP and 
the absence of incentives for companies to take risk and propose novel approaches”.224 
They suggested the Government had “long recognised an unresolved challenge”, a view 
supported by Professor Sir Mark Walport of UKRI.225
149. Felicity Burch of the CBI called for “a bigger, more strategic approach” to procurement:
You need the Government Departments pulling together to deliver better 
procurement outcomes and more innovation through procurement [ … ] 
The issue is whether SBRI is the right tool. Even £200 million will not be 
enough really to shift the dial on the UK landscape [ … ] The Government 
need to take a more holistic look at their procurement practices. SBRI is 
probably part of it, but they should look at how they support research and 
innovation more generally. Departmental expenditure on R&D needs to be 
part of that mix. Potentially, it would be the bigger shift.226
150. The then Minister acknowledged the potential of procurement, stating:
I see huge opportunities in looking at where, through public procurement, 
we can deliver potential opportunities for co-investment in future R&D. It 
has been tried before; it has not always been so successful, and I am trying 
to understand why.227
This analysis will be difficult given the quality of Government procurement data is 
relatively poor, as highlighted by the Institute for Government.228 This illustrates an 
ongoing concern that we addressed in our Digital Government inquiry, which looked 
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at how well the Government and its agencies deployed their datasets to maximise their 
value for money, effectiveness and delivery, and how well ‘open data’ arrangements were 
operating.229
151. The Industrial Strategy rightly recognises the power of public procurement as a 
demand-side driver of potential R&D spending. However, there does not appear to 
be any further development of the strategy to exploit this potential, despite it being a 
long-recognised issue.
152. Alongside increasing the size and reach of SBRI, the Government should produce 
a procurement strategy and communications plan for addressing businesses that 
specifically identifies innovation opportunities and promotes innovation-friendly 
practices across all types of procurement. It should address barriers currently perceived 
by the business community, such as treatment of risk and intellectual property. The 
benefits of a central portal that collates procurement opportunities from across 
Government should be pursued.
R&D tax credits
153. R&D tax credits are a tax relief designed to encourage greater R&D spending. 
There are currently two schemes for claiming relief, the SME Scheme, aimed at small 
and medium-sized enterprises, and the Research and Development Expenditure Credits 
scheme (RDEC) for larger companies, resulting in either a corporation tax reduction or a 
cash credit for loss-making firms.230
154. The latest HMRC Evaluation of R&D Tax Credits is from 2015 and estimates that for 
every pound spent on R&D tax credits, between £1.53 and £2.35 is additionally spent on 
R&D by UK companies, which appears in line with previous international studies.231 Many 
of the written submissions to our inquiry quoted this evidence in their support for R&D 
tax credits.232 The CBI explained that the system was “hugely valued” and that “in CBI 
surveys access to tax credits is one of the areas where businesses are most likely to rate the 
UK as world class”.233
155. Despite this support, there were still suggestions for potential improvements. 
Submissions by Oxford University and the Russell Group highlighted that the system 
could be simplified, for example by making all company sponsorship of university research 
eligible for credit.234 CaSE suggested that the definition of R&D for tax purposes needed 
to be updated as it was “currently too focused on physical products”; suggestions included 
the “purchase of data for research purposes and digital infrastructure to support R&D 
within the definition, as some other countries have done already.”235 Felicity Burch of the 
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CBI suggested that “the R&D tax credit does not currently include the use of algorithms 
in research, but for a lot of businesses that is a new and growing area and could open up 
opportunities for the sector”.236
156. However, we recognise that many of the organisations that support the tax credit system 
are those who currently benefit from the scheme, or those who could benefit in future. At 
the same time tax credits may be more important for international tax competition, for 
retaining R&D intensive firms in the UK or attracting new R&D investment, than for 
any intrinsic effectiveness in driving innovation. As a tax incentive it may also encourage 
gaming—a HMRC-HMT consultation in to preventing abuse of the R&D tax relief for 
SMEs ran from March to May 2019 and may be legislated for in the Finance Bill 2019–20.237
157. David Connell was more sceptical about the impact of R&D tax credit spending, 
suggesting that “the Government subsidy seems merely to have substituted for aggregate 
spending from company generated funds”.238 His evidence cited the UK’s business R&D 
intensity, which was around 1.1% of GDP in 1999–2000 and at a similar level in 2015–16, 
despite more than £20bn being spent through the scheme, and he noted that industrial 
competitors such as Germany, Finland and Sweden have no such tax credits but maintain 
high levels of R&D. Analysis by the Institute for Public Policy Research, which built on 
HMRC’s findings but incorporated methods used by the Irish Department of Finance, 
estimated that “between 57 and 80 per cent of R&D tax credits are deadweight, subsidising 
spending which would have happened anyway, at an annual cost of £1.8–1.9 billion.”239 
The Academy of Social Sciences suggested that this analysis should encourage further 
work on how to stimulate private investment.240
158. David Connell suggested several possible improvements to the system, 
including making the credit applicable to only increases in R&D spend, and attempting 
to pay the credit as a voucher, which could be redeemed for development contracts 
with universities, independent research organisations or (other) SMEs.241 These vouchers 
had the potential to be designed as regionally-specific to further encourage regional re-
balancing in line with Government priorities.
159. The Government has spent more than £20bn through the R&D tax credit scheme. 
It is popular and widely supported, but often this support is from those who have 
benefited from its generosity or focus on the quantity rather than quality of support. 
We welcome the Treasury consultation aimed at preventing abuse of the system.
160. The Treasury and HMRC should undertake updated analysis of the tax credit system 
which addresses the issue of deadweight spending and reassesses current estimates of 
additionality of R&D spending by business. This analysis should also evaluate the benefit 
of other potential changes to the scheme to encourage additionality of spending, and 
methods of targeting credit for regional or sectoral priorities, to encourage alignment 
with the goals of the Industrial Strategy.
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Patient capital
161. As described by the Financial Conduct Authority (FCA), ‘patient capital’ refers to 
a broad range of alternative investment assets intended to deliver long-term returns, 
including infrastructure, real estate, private debt or equity, and venture capital.242 The 
Government’s Patient Capital Review specifically sought to address the issues of financing 
growth in innovative firms.243 Their consultation identified a range of indicators 
suggesting that the UK is lagging behind its potential in the longer-term process of scaling 
up successful start-ups.244 Whilst venture capital investment in the UK is currently valued 
at around £4 billion per year, if the UK achieved the same level of investment as the USA 
relative to GDP, it would be around another £4 billion per year higher.
162. The review identified a number of causes for the lack of effective patient capital 
investment in the UK. One root cause was the UK’s historically thin market for patient 
investment, stemming from a lack of critical mass in parts of the market. On the demand 
side there may be a lack of serial entrepreneurs and inconsistency in the success of 
University spin outs.
163. Following the publication of the Government’s patient capital consultation, we wrote 
to the then Chancellor in September 2017, ahead of the first Autumn Budget. In this letter 
we agreed with the identification of pension funds as a potential untapped source of 
capital, with the UK defined-benefit pension funds holding around £1.3 trillion in assets 
but a low level of investment in patient capital, potentially as a result of perceived over-
interpretation of the legal responsibility of pension fund trustees to act ‘prudently’.245
164. At Budget 2018, the Government published an update to the consultation246 which 
outlined its progress on implementing the patient capital action plan, and new measures 
were announced to support defined contribution (DC) pension schemes to invest in 
patient capital:247
• “through the British Business Bank, the government will support pension funds 
to invest in growing UK businesses. Several of the largest defined contribution 
pension providers in the UK have committed to work with the British Business 
Bank to explore options for pooled investment in patient capital”;
• “the FCA will publish a discussion paper by the end of 2018 to explore how 
effectively the UK’s existing fund regime enables investment in patient capital”; 
and
• “the FCA will consult by the end of 2018 on updating the permitted links 
framework to allow unit-linked pension funds to invest in an appropriate range 
of patient capital assets”.
242 Financial Conduct Authority, Patient Capital and Authorised Funds, Dec 2018
243 HM Treasury, Patient Capital Review, Jan 2017
244 HMT Financing growth in innovative firms pp 11–12;namely a proportionally lower number of young large listed 
companies, a lower proportion of R&D being performed by younger companies, a lower number of “unicorn” 
firms” (a private company valued at more than $1 billion (US), fewer firms growing to scale, and a tendency for 
UK investors to exit at a relatively early stage, reducing firms’ ability to scale up.
245 Letter from Rt Hon Norman Lamb MP to Rt Hon Philip Hammond MP, 12 Nov 2017
246 HMT Financing growth in innovative firms: one-year on
247 HMT Budget 2018 para 4.43
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165. The British Business Bank launched the British Patient Capital248 programme in 2018 
to invest in commercially viable venture capital funds. It began with an initial £400 million 
seed finance, and an aim of investing £2.5 billion over the next decade, leveraging further 
private investment to create a £7.5 billion fund. This investment should help venture 
capital funds improve the breadth and depth of their experience. The FCA discussion249 
and consultation250 papers have been published, with final rules (and attendant enhanced 
risk warnings) intended for publication in late 2019.
166. The evidence we received appeared broadly supportive of the Patient Capital Review 
analysis and recommendations,251 with the BioIndustry Association in particular 
urging us to encourage the Government to act quickly to increase private investment by 
pension funds.252 Universities UK suggested in their submission that the Patient Capital 
investment fund was a “positive step in the right direction”, but what was needed now 
was a “coherent framework that sets out a strategy on stimulation of private investment 
in R&D”.253 The Academy of Medical Sciences called the establishment of British Patient 
Capital a “highly positive step”, but stressed it was “vital” that investment was delivered 
across the whole country, as venture capital remains “extremely elusive outside of the 
South East of England”.254
167. David Connell also suggested that there was a requirement for non-dilutive finance for 
start-ups “to help prevent successful entrepreneurs being forced by financial investors into 
early trade sales, with the resulting truncation of growth in UK based operations”, adding 
that recent patient capital measures did not appear to address this.255
168. The Patient Capital Review was a welcome step by the Government to identify 
important issues in the demand and supply of long-term capital. We welcome the 
subsequent work to help clarify the guidance for investors so as to make patient 
capital more accessible to pension funds, which we have previously also identified as a 
significant potential source of funding. However, such clarification may be insufficient 
to entice investors towards new assets and investments if they still perceive they are at 
a disadvantage due to information asymmetry and lack of experience. We hope that 
the launch of British Patient Capital and the work on pooled investment vehicles will 
address this issue. We also hope additional influence over dimensions of balance, such 
as regional concentration of funding, can further be addressed by this investment.
169. We recommend that the Government act quickly on the recommendations of the 
FCA review of regulations relating to patient capital and permitted links, and publish a 
further update at Budget 2020 that details the additional pension fund investment that 
has been stimulated by these rule changes. Further review should be considered if there 
has not been a step change, maintaining a commitment to exploiting the considerable 
funding potentially available through both defined-contribution and defined benefit 
pension schemes.
248 British Patient Capital
249 Financial Conduct Authority, Patient Capital and Authorised Funds, Dec 2018
250 Financial Conduct Authority, Consultation on proposed amendment of COBS 21.3 permitted links rules, Dec 
2018
251 UCL (BER0014) para 30, University of Oxford (BER0021) para 32
252 BioIndustry Association (BER0030) para 7.10
253 Universities UK (BER0044) para 32
254 Academy of Medical Sciences (BER0069) para 60
255 Mr David Connell (BER0006)
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Conclusions and recommendations
Level of ambition of the 2.4% target
1. Additional frontloaded funding will be key for reaching the 2.4% target, but it 
clearly is not sufficient. It is also important to ensure that the capacity of the UK 
economy and research system enables R&D expenditure to be used efficiently and 
effectively. Creating sufficient leverage of private sector investment will be crucial. 
The Government should consider whether a separate Government R&D spending 
target, either as a proportion of GDP or in real terms, would benefit the current 
national target. (Paragraph 27)
2. We welcome the Government’s target for R&D spending which, if achieved, would 
represent a significant increase in the research intensity of the UK economy. 
However, the difficulty in achieving the target should not be underestimated, and 
will require successful coordination of public spending and further increases in 
private investment. (Paragraph 33)
3. We welcome the commitments by UKRI and BEIS to make a strong case at the 
Spending Review, which we had expected to be this autumn, for the additional 
funding required to reach the 2.4% target by 2027. Given the stretch of the target, 
it is apparent that additional public spending is likely to gain greater traction if 
it is undertaken earlier, thus increasing the potential for leveraging private sector 
spending. (Paragraph 34)
4. Both UKRI and BEIS have committed to publishing roadmaps to show the path 
to 2.4%. It is our understanding that given the nature of both public and private 
investment required to reach the target, these roadmaps will address the landscape 
influencing R&D spending, including the wider Government policies and pillars 
of the Industrial Strategy (ideas, people, infrastructure, business environment, and 
places). (Paragraph 35)
5. It is not clear whether the Government’s recent commitment to “set out plans to 
significantly boost public R&D funding”, which it had promised this autumn, relate 
specifically to the roadmaps, high-level long-term funding plans, or simply greater 
clarification of the BEIS capital budget for next year, which was not fully set in the 
recent Spending Round. Assuming that a multi-year funding commitment is made, 
a “significant boost” should suitably reflect the frontloaded investment that we have 
established is required. We are pleased that such decisions will not be delayed until the 
2020 Spending Review and urge UKRI and BEIS to make the ‘strong case’ we expect 
of them. (Paragraph 36)
6. We hope that the promise of providing “greater long-term certainty to the scientific 
community” indicates both a long-term funding commitment and the detailed 
plans we expect to be contained in the roadmaps. If not, we strongly recommend that 
both UKRI and BEIS publish their promised comprehensive roadmaps to illustrate 
the intended path to the 2.4% target as soon as possible, and no later than the end of 
2019 following confirmation of Government funding plans. These should demonstrate 
an integrated approach between UKRI and BEIS that suitably reflects the strengths 
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and prospects of the UK economy. These plans should also be developed beyond 2027 
to ensure that travel towards the longer-term 3% target, indicating how momentum 
will be maintained and when more detailed plans for this target will be produced. 
(Paragraph 37)
UKRI and the R&D landscape
7. The complexity of the R&D ecosystem has been well documented and means that 
understanding the interaction of organisation, funding and policies is difficult. 
Some complexity may be inevitable given the diversity of policy goals and actors. 
(Paragraph 42)
8. UKRI and BEIS should ensure that their roadmaps on how the UK will reach the 
2.4% target detail key areas of potential conflict or policy overlap resulting from their 
choice of policy mix in this complex environment. Unnecessary complexities should 
be identified and removed as part of the mapping process. In order to aid public 
understanding they should update the Dowling Review schematic, including details of 
the main R&D funding streams available through the Industrial Strategy and UKRI. 
(Paragraph 42)
9. The creation of UKRI created a significant opportunity for improving the strategy 
and coordination of research funding. However, there remain significant risks in 
introducing a new strategic oversight, and in gaining the support of the wide range 
of stakeholders, including the public, with whom UKRI will interact. The overall 
success of UKRI is dependent on overcoming these challenges at an early stage. 
(Paragraph 62)
10. We recognise the complexity of addressing the balance of funding of the dual 
support system and that this is a fundamental remit of UKRI. Creating a robust 
evidence base for this assessment will be crucial, and we recognise that UKRI 
strategy is to approach the task cautiously and without any sudden shifts in funding. 
(Paragraph 63)
11. In line with the approach taken in this Report, UKRI should also assess and report 
on other dimensions of balance such as the regional concentration of funding, the 
balance between research and innovation, and the balance between capital and 
current spending, in a similar manner to its analysis of the dual support system. We 
believe more immediate changes to funding are appropriate to influence the current 
balance in these areas. There are many possible ‘balances’ or policy mixes, and this 
political choice should be transparently set out. (Paragraph 64)
12. We support UKRI’s commitment to evaluation, and understand the inherent 
difficulties in analysing the impact of research and innovation and attributing it to 
wider outcomes, which may occur after a significant time-lag. We recognise that in 
some cases evaluation will be impossible and UKRI should be explicit that this is 
the case and explain why. Unfortunately the current focus appears too strongly to 
follow traditional metrics, measuring outputs such as publications and patents that 
should only be one element of evaluation. (Paragraph 71)
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13. Research on research is an increasingly important field, and we recommend that 
UKRI consider a dedicated approach to supporting it, including how this research is 
incorporated into UKRI strategy and its assessment of the balance of R&D funding. 
Relatedly, UKRI should attempt to analyse the benefit gained by its creation through 
its enhanced ability to capture data across research councils and through cross-cutting 
funds. (Paragraph 72)
14. We recommend that UKRI also develops a ‘big data’ focus for evaluation. It should 
publish a plan for creating and investing in new data sources and analysis techniques 
beyond traditional measures of patents and publications. (Paragraph 73)
UKRI influence on the balance of R&D spending
15. Decisions about what balances to strike are essentially political. The current balance 
and concentration of funding is the result of previous policy choices, and this should 
be explicitly recognised. But the various balances discussed in this Report should 
take account of current goals and needs rather than reflecting those of past decades. 
(Paragraph 80)
16. Finding the correct balance in each area may be impossible, but it is the policy mix 
needed to best support R&D that is important rather than just the performance of 
individual policies. Although optimal balance might not be identifiable, in many 
cases where evidence recommended a need for increased funding, such increases 
might be more feasible and palatable in an environment with an increasing spending 
envelope as they will not necessitate reallocation of funding from elsewhere. 
(Paragraph 81)
17. We recognise that the dual funding system of block grants and project-based 
research council funding has been crucial to the success of UK universities, and 
that maintaining this system with ‘appropriate balance’ will be a key function of 
UKRI. There may be no optimal balance, but trying to reach an appropriate balance 
in the light of current policy goals is a key political choice and should be made 
in a transparent and accountable fashion. UKRI should continually monitor the 
appropriateness of balances struck in the operation of the dual support system and 
publish the advice given to the Government, alongside its analysis and commentary, 
at regular intervals. (Paragraph 89)
18. The flat profile of QR funding in recent years suggests it has not been prioritised 
in funding decisions. The announcement of a £45 million increase in mainstream 
QR funding by Research England in July 2019 indicates that there may be a change 
in this focus, and a recognition of the benefits of un-hypothecated budgets which 
allow universities to maintain agility and develop their own areas of expertise. We 
recommend that focus on QR funding is maintained in future considerations, and 
that QR should continue to be prioritised to address previous real-terms reductions in 
funding. (Paragraph 90)
19. UKRI should review the quality-related (QR) formula which has been responsible for 
increasing concentration of regional spending, paying attention to the formula used 
in Scotland which has been less geared towards driving concentration. (Paragraph 91)
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20. Whilst QR funding provides a stability of funding over the course of the seven-
year REF cycle, we also recognise that these timeframes create barriers for smaller 
but potentially fast-growing institutions or areas of excellence who receive lower 
QR allocations. We recommend that in UKRI’s ongoing evaluation work it reviews 
whether additional support for these institutions should be provided, possibly through 
specific gearing of investment across the REF period, through additional review 
periods for smaller bodies, or through separate QR stream for smaller and specialist 
institutions. (Paragraph 92)
21. Place is a key focus within both the Industrial Strategy and the UKRI strategic 
prospectus and development plan. In the context of the regional concentration of 
research funding, the aim should be to build further research excellence outside 
of its existing predominance in the South East of England. We strongly agree that 
additional regional funding should not be to the detriment of this ‘golden triangle’, 
and excellence in this area should continue to be rewarded, recognising that this is 
a tide that lifts all boats in terms of international recognition of the UK as a place of 
quality research. However, in order to contribute to the 2.4% R&D target, regional 
strengths will need to be harnessed and cultivated. (Paragraph 100)
22. For wider regional growth to succeed, expertise and infrastructure beyond 
universities will be required, as envisaged in the wider Industrial Strategy. For 
UKRI, the main lever with which to stimulate regional excellence is through the 
Strength in Places Fund (SIPF). The SIPF is still in its infancy, but its rationale and 
its goals remain somewhat opaque and it is too modest to drive any significant 
rebalancing of investment given the strength of existing drivers of increasing regional 
concentration in funding. Whilst the fund is still in its infancy, it appears to be a 
more innovation-orientated approach that appears too small to drive a significant 
re-balancing of investment given the current level of regional concentration in 
funding. (Paragraph 101)
23. We recommend that UKRI and BEIS substantially increase the size of the Strength in 
Places Fund given it appears to be the primary lever through which it is attempting to 
influence the regional concentration of funding and create new centres of excellence 
beyond the golden triangle. It should further clarify the rationale and expectations 
of this expanded programme. This should include the intended evaluation approach 
and key metrics for assessing the level of regional concentration of funding and the 
outcomes of this funding. (Paragraph 102)
24. We understand that the distinction between pure and applied research is a contested 
definition and as such it does not appear to be a dimension of balance on which 
funding decisions can usefully be made, whilst also understanding the importance 
of maintaining funding for pure research as a foundation of other benefits and 
dimensions of balance. (Paragraph 107)
25. Since the 1980s the UK has had a very different profile of scientific research spending 
versus technological development and innovation spending to other developed 
countries. As a result the public sector science base, and the dual support system, 
have been expected to do almost all the heavy lifting of driving and supporting 
innovation, together with an emphasis on commercialisation of academic science. 
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This generic science-based innovation policy may explain the paradox that the 
research focused UK system has felt progressively more ‘applied’ and directed to 
many of the researchers working within it. (Paragraph 111)
26. Since the global financial crisis successive Governments have made tentative steps 
back towards more active support for technological development, with milestones 
including the establishment of Innovate UK and the Catapult Network. The Industrial 
Strategy and the Industrial Strategy Challenge Fund are the latest milestones in this 
direction of travel. Funding for the development of new technologies is not the only 
way Governments support innovation, but is an important part of any Industrial 
Strategy. Continued growth in technological development and innovation funding 
should also allow a rethinking of the ‘innovation focus’ of the ‘basic’ public sector 
science base. (Paragraph 112)
27. The balance across research disciplines should be easier to monitor and adjust 
under UKRI. Historic patterns clearly should not be maintained for their own sake. 
However, we are concerned that the Strategic Priorities Fund (SPF) may have not 
been established in a way that effectively addresses this issue. We recommend that 
UKRI review the SPF and ensure that individual research councils are not exerting 
excessive influence on what is intended to be a cross-council, multi-disciplinary focus. 
(Paragraph 117)
28. Future consideration of the balance between disciplines must include robust 
evaluation of research areas within each discipline. We find the case regarding 
entrenched concentration of research analysed in The Biomedical Bubble compelling. 
UKRI analysis should widen this approach and conduct relevant cost-benefit analysis 
of larger research areas within different disciplines to establish whether R&D spending 
remains productive. (Paragraph 118)
29. We welcome the opportunity to redress reductions in capital investment for research. 
The UKRI roadmap represents an opportunity to consider where investment can 
be focused and most effective in contributing to ongoing research excellence and 
to the wider goals of the 2.4% target. In order for UKRI to take ownership of the 
‘batteries not included’ issue, we recommend that decisions for investment include 
consideration of the coordination of capital and revenue funding and the long-term 
requirements of new and existing investments. Major capital investment project plans 
should explicitly state assumptions regarding future QR or research council funding 
that may be required to staff or run them. (Paragraph 123)
30. There are concerns that ring-fencing of funds for specific goals such as overseas 
development assistance will further diminish the ability of universities to undertake 
responsive mode funding. This is related to wider concerns regarding quality-
related funding and the implications for basic research from a perceived focus on 
application-led research. Whilst we do not currently see this as a pressing concern, 
UKRI should continue to monitor this balance and detail the proportion of ring-
fenced funding on ODA in its publications. (Paragraph 127)
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Beyond UKRI–wider balance
31. There are a myriad of funding sources for research and innovation, many of them 
provided by UKRI. However, Government departments outside of UKRI, notably 
the NHS and the Ministry of Defence, invest a significant amount in R&D. The 
Government needs to make it as easy as possible for businesses to locate and access 
these opportunities. (Paragraph 132)
32. The Government should conduct a review of all the funding streams and opportunities 
for R&D support advertised across Government. It should create a central linking 
point or web portal for access, and consider how this is advertised, particularly to 
SMEs. (Paragraph 133)
33. The Government strategy for reaching 2.4% R&D investment, which we hope will be 
illustrated in the promised roadmap, should highlight the cross-Government R&D 
investment that is undertaken, particularly by large departments such as the NHS 
and Defence. The roadmap should include detail on UKRI’s role in coordinating this 
investment. The creation of UKRI represents an opportunity for it to operate as the 
ultimate steward of this system. (Paragraph 136)
34. While departments should be free to invest in areas of individual importance, UKRI 
should maintain a strategic overview of potential synergies with UKRI funding and the 
impact on skills and infrastructure that this creates. It should also analyse the potential 
impact of this cross-Government funding on dimensions of balance such as regional 
concentration of spending that we have addressed in this inquiry. (Paragraph 137)
35. We agree with the Connell Review that the Small Business Research Initiative has 
a “unique and valuable role to play in the innovation and procurement landscape”, 
supporting UK businesses in developing innovative new products while enabling 
public sector bodies to source innovative solutions to the challenges they face. 
However, the Government’s response to the Connell Review so far is limited. 
(Paragraph 143)
36. The GovTech Catalyst only supports public bodies in sourcing digital technology 
solutions and the three-year, £20m GovTech Fund is significantly smaller than the 
£250m that the Connell Review recommended to be spent per annum through 
SBRI, or the £200m target the Government had for SBRI spending in 2014–15, 
and should not be viewed as a replacement. We recommend that the Government 
fully adopts the recommendations of the Connell Review, and establishes a central 
SBRI fund with a National Board to oversee its delivery as part of the 2020 Spending 
Review. (Paragraph 144)
37. The Government should consider using the SBRI to procure the web portal for 
innovation support detailed in the recommendation at paragraph 133, allowing 
external experts and potential users to create an intuitive directory and system for 
coordinating future innovation support schemes. (Paragraph 145)
38. The Industrial Strategy rightly recognises the power of public procurement as a 
demand-side driver of potential R&D spending. However, there does not appear to 
be any further development of the strategy to exploit this potential, despite it being 
a long-recognised issue. (Paragraph 151)
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39. Alongside increasing the size and reach of SBRI, the Government should produce 
a procurement strategy and communications plan for addressing businesses that 
specifically identifies innovation opportunities and promotes innovation-friendly 
practices across all types of procurement. It should address barriers currently perceived 
by the business community, such as treatment of risk and intellectual property. The 
benefits of a central portal that collates procurement opportunities from across 
Government should be pursued. (Paragraph 152)
40. The Government has spent more than £20bn through the R&D tax credit scheme. 
It is popular and widely supported, but often this support is from those who have 
benefited from its generosity or focus on the quantity rather than quality of 
support. We welcome the Treasury consultation aimed at preventing abuse of the 
system. (Paragraph 159)
41. The Treasury and HMRC should undertake updated analysis of the tax credit system 
which addresses the issue of deadweight spending and reassesses current estimates 
of additionality of R&D spending by business. This analysis should also evaluate the 
benefit of other potential changes to the scheme to encourage additionality of spending, 
and methods of targeting credit for regional or sectoral priorities, to encourage 
alignment with the goals of the Industrial Strategy. (Paragraph 160)
42. The Patient Capital Review was a welcome step by the Government to identify 
important issues in the demand and supply of long-term capital. We welcome the 
subsequent work to help clarify the guidance for investors so as to make patient 
capital more accessible to pension funds, which we have previously also identified 
as a significant potential source of funding. However, such clarification may be 
insufficient to entice investors towards new assets and investments if they still 
perceive they are at a disadvantage due to information asymmetry and lack of 
experience. We hope that the launch of British Patient Capital and the work on 
pooled investment vehicles will address this issue. We also hope additional influence 
over dimensions of balance, such as regional concentration of funding, can further 
be addressed by this investment. (Paragraph 168)
43. We recommend that the Government act quickly on the recommendations of the FCA 
review of regulations relating to patient capital and permitted links, and publish a 
further update at Budget 2020 that details the additional pension fund investment 
that has been stimulated by these rule changes. Further review should be considered 
if there has not been a step change, maintaining a commitment to exploiting the 
considerable funding potentially available through both defined-contribution and 
defined benefit pension schemes. (Paragraph 169)
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Formal minutes
Monday 9 September 2019
Members present:
Norman Lamb, in the Chair
Bill Grant
Darren Jones
Stephen Metcalfe
Graham Stringer
Draft Report (Balance and effectiveness of research and innovation spending), proposed by 
the Chair, brought up and read.
Ordered, That the draft Report be read a second time, paragraph by paragraph.
Paragraphs 1 to 169 read and agreed to.
Summary agreed to.
Resolved, That the Report be the Twenty-first Report of the Committee to the House.
Ordered, That the Chair make the Report to the House.
Ordered, That embargoed copies of the Report be made available (Standing Order No. 
134.).
[Adjourned to a day and time to be fixed by the Chair.
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Witnesses
The following witnesses gave evidence. Transcripts can be viewed on the inquiry publications 
page of the Committee’s website.
Tuesday 20 November 2018
Sir Paul Nurse, Director, The Francis Crick Institute, Kirsten Bound, 
Executive Director of Research, Analysis and Policy, Nesta, Professor James 
Wilsdon, Professor of Research Policy, University of Sheffield, and Chair, 
Academy of Social Sciences Policy Working Group, and Dr Sarah Main, 
Executive Director, Campaign for Science and Engineering Q1–47
Ernesto Fernandez Polcuch, Chief of Section, Science Policy and 
Partnerships, UNESCO, Paris, Professor Jakob Edler, Executive Director, 
Fraunhofer Institute for Systems and Innovation Research, Germany, and 
Dr Jos van den Broek, Senior Researcher, Rathenau Instituut, Netherlands Q48–102
Professor Paul Nightingale, Professor of Strategy, Science Policy Research 
Unit, University of Sussex, and (designate) Director of Strategy and 
Operations, ESRC, and Professor Joanna Chataway, Head of Department, 
Science, Technology, Engineering and Public Policy, University College 
London, and Deputy Director of Science Policy Research Unit, University of 
Sussex Q103–137
Tuesday 18 December 2018
Keith Thompson, Chair, Catapult CEO network, and CEO, Cell and Gene 
Therapy Catapult, Professor Richard Brook, President, Association 
of Innovation, Research & Technology Organisations, David Connell, 
Senior Research Fellow, Centre for Business Research, Cambridge Judge 
Business School, and Felicity Burch, Director of Innovation and Digital, 
Confederation of British Industry Q138–213
Dr Robert Massey, Deputy Executive Director, Royal Astronomical Society, 
Professor Dame Ann Dowling, President, Royal Academy of Engineering, 
Professor Neil Hall, Director, Earlham Institute, and Dr Charmaine Griffiths, 
Chief Operating Officer, The Institute of Cancer Research Q214–263
Thursday 28 February 2019
Professor Graeme Reid, Professor of Science and Research Policy, UCL, 
Professor Colette Fagan, Russell Group, and Gordon McKenzie, Chief 
Executive, GuildHE Q264–343
Dr Peter O’Brien, Executive Director, Yorkshire Universities, Professor 
Jonathan Seckl, Vice-Principal, Planning, Resources and Research Policy, 
University of Edinburgh, Professor Anthony Hollander, Pro-Vice Chancellor 
for Research and Impact, University of Liverpool, and Sarah Haywood, 
Chief Executive, MedCity Q344–386
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Tuesday 26 March 2019
Sir Mark Walport, Chief Executive, and Rebecca Endean, Director of 
Strategy, UK Research and Innovation Q387–450
Chris Skidmore MP, Minister of State for Universities, Science, Research and 
Innovation, Jenny Dibden, Director, Science Research and Innovation, and 
Harriet Wallace, Director, International Science and Innovation Directorate, 
Department for Business, Energy and Industrial Strategy Q451–501
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Published written evidence
The following written evidence was received and can be viewed on the inquiry publications 
page of the Committee’s website.
BER numbers are generated by the evidence processing system and so may not be complete.
1 Academy of Medical Sciences (BER0069)
2 Academy of Social Sciences (BER0034)
3 AIRTO Ltd (BER0013)
4 Alex Stobart (BER0102)
5 Alzheimer’s Research UK (BER0027)
6 Anderson Law LLP (BER0001)
7 Association of Medical Research Charities (BER0049)
8 BAE Systems plc (BER0003)
9 BioIndustry Association (BER0030), (BER0101)
10 Campaign for Science and Engineering (BER0065)
11 Cancer Research UK (BER0043)
12 Coventry University (BER0023)
13 Denise Yates (BER0105)
14 Department for Business, Energy and Industrial Strategy (BER0064), (BER0090), 
(BER0096)
15 Design Council (BER0085)
16 Designability (BER0009)
17 Dr Rachel Oliver and others (BER0056)
18 Dr Stuart Calimport (BER0074)
19 Earlham Institute (BER0071), (BER0084), (BER0099)
20 Fight for Sight (BER0046)
21 Fleet Renewables Ltd (BER0100)
22 Greater London Authority and MedCity (BER0015)
23 GuildHE (BER0055)
24 GW4 Alliance (BER0045)
25 Iain MacKenzie (BER0104)
26 Imperial College London (BER0067)
27 Intergenerational Foundation (BER0103)
28 Jisc (BER0047)
29 John Innes Centre (BER0066)
30 King’s College London (BER0054)
31 Knowledge Transfer Network (BER0048)
32 MedCity (BER0093)
33 Medical Schools Council (BER0028)
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34 Miricyl (BER0106)
35 Mr David Connell (BER0006), (BER0082)
36 Mr Jasper Tomlinson (BER0007)
37 Mr Jerome Jackson (BER0092) (BER0094)
38 MSD (BER0041)
39 National Physical Laboratory (BER0031)
40 Nesta (BER0072), (BER0081)
41 Norwich Research Park (BER0079)
42 Photonics Leadership Group (BER0058)
43 PraxisAuril (BER0075)
44 Prime Minister’s Council for Science and Technology (BER0088)
45 Productivity Insights Network and Innovation Caucus (BER0059)
46 Professor Andrew Webster (BER0077)
47 Professor Dame Athene Donald (BER0019)
48 Professor Evan Parker, University of Warwick (BER0010)
49 Professor Graeme Reid, University College London (BER0097)
50 Professor Joanna Chataway (BER0078)
51 Professor Jonathan Jones, The Sainsbury Laboratory (BER0020)
52 Professor Michael Ferguson (BER0005)
53 Professors Richard Jones and Professor James Wilsdon, University of Sheffield 
(BER0051)
54 Prospect (BER0017)
55 Rodney Basford (BER0095)
56 Rolls-Royce (BER0022)
57 Rothamsted Research (BER0057)
58 Royal Academy of Engineering (BER0061)
59 Royal Astronomical Society (BER0018)
60 Royal Society of Biology (BER0076)
61 Royal Society of Chemistry (BER0037)
62 Royal Society of Edinburgh / Learned Society of Wales (BER0073)
63 Russell Group (BER0060), (BER0091)
64 STOPAIDS (BER0083)
65 The Association of the British Pharmaceutical Industry (ABPI) (BER0062)
66 The British Academy (BER0042)
67 The British Academy of Management (BAM) and the Chartered Association of 
Business Schools (Chartered ABS) (BER0029)
68 The Catapult Network (BER0032)
69 The Confederation of British Industry (CBI) (BER0026)
70 The Geological Society (BER0053)
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71 The Institute of Cancer Research (BER0025), (BER0086)
72 The Physiological Society (BER0039)
73 The Royal Society (BER0070)
74 The Shelford Group (BER0035)
75 TWI Ltd (BER0038)
76 UCL (BER0014)
77 UK Computing Research Committee (BER0004)
78 UK Innovation & Science Seed Fund (BER0050)
79 UK Research and Innovation (BER0063), (BER0098)
80 UNESCO (BER0080)
81 Universities Scotland (BER0016)
82 Universities UK (BER0044), (BER0089)
83 Universities Wales (BER0033)
84 University of Edinburgh (BER0008)
85 University of Nottingham (BER0052)
86 University of Oxford (BER0021)
87 University of Reading (BER0040)
88 Wellcome Trust (BER0068)
89 WMG (BER0012)
90 Yorkshire Universities (BER0024)
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List of Reports from the Committee 
during the current Parliament
All publications from the Committee are available on the publications page of the 
Committee’s website. The reference number of the Government’s response to each Report 
is printed in brackets after the HC printing number.
Session 2017–19
First Report Pre-appointment hearing: chair of UK Research & 
Innovation and executive chair of the Medical Research 
Council
HC 747
Second Report Brexit, science and innovation HC 705
Third Report Genomics and genome editing in the NHS HC 349
Fourth Report Algorithms in decision-making HC 351
Fifth Report Biometrics strategy and forensic services HC 800
Sixth Report Research integrity HC 350
Seventh Report E-cigarettes HC 505
Eighth Report An immigration system that works for science and 
innovation
HC 1061
Ninth Report Flu vaccination programme in England HC 853
Tenth Report Research integrity: clinical trials transparency HC 1480
Eleventh Report Evidence-based early years intervention HC 506
Twelfth Report Quantum technologies HC 820
Thirteenth Report Energy drinks and children HC 821
Fourteenth Report Impact of social media and screen-use on young 
people’s health
HC 822
Fifteenth Report Evidence-based early years intervention: Government’s 
Response to the Committee’s Eleventh Report of 
Session 2017–19
HC 1898
Sixteenth Report ‘My Science Inquiry’ HC 1716
Seventeenth Report Japanese knotweed and the built environment HC 1702
Eighteenth Report Digital Government HC 1455
Nineteenth Report The work of the Biometrics Commissioner and the 
Forensic Science Regulator
HC 1970
Twentieth Report Clean Growth: Technologies for meeting the UK’s 
emissions reduction targets
HC 1454
First Special Report Science communication and engagement: Government 
Response to the Committee’s Eleventh Report of 
Session 2016–17
HC 319
Second Special Report Managing intellectual property and technology 
transfer: Government Response to the Committee’s 
Tenth Report of Session 2016–17
HC 318
65 Balance and effectiveness of research and innovation spending 
Third Special Report Industrial Strategy: science and STEM skills: 
Government Response to the Committee’s Thirteenth 
Report of Session 2016–17
HC 335
Fourth Special Report Science in emergencies: chemical, biological, 
radiological or nuclear incidents: Government 
Response to the Committee’s Twelfth Report of 
Session 2016–17
HC 561
Fifth Special Report Brexit, science and innovation: Government Response 
to the Committee’s Second Report
HC 1008
Sixth Special Report Algorithms in decision-making: Government Response 
to the Committee’s Fourth Report
HC 1544
Seventh Special Report Research integrity: Government and UK Research and 
Innovation Responses to the Committee’s Sixth Report
HC 1562
Eighth Special Report Biometrics strategy and forensic services: 
Government’s Response to the Committee’s Fifth 
Report
HC 1613
Ninth Special Report An immigration system that works for science 
and innovation: Government’s Response to the 
Committee’s Eighth Report
HC 1661
Tenth Special Report Research integrity: clinical trials transparency: Health 
Research Authority Response to the Committee’s Tenth 
Report
HC 1961
Eleventh Special Report Quantum technologies: Government Response to the 
Committee’s Twelfth Report
HC 2030
Twelfth Special Report Impact of social media and screen-use on young 
people’s health: Government Response to the 
Committee’s Fourteenth Report
HC 2120
Thirteenth Special 
Report
Japanese knotweed and the built environment: 
Government Response to the Committee’s 
Seventeenth Report
HC 2600
